Reproductive health in women with childhood-onset type 1 diabetes in Finland by Sjöberg, Lena
Department of General Practice and Primary Health Care Clinicum
Faculty of Medicine 
Doctoral Programme in Population Health 
University of Helsinki
REPRODUCTIVE HEALTH IN WOMEN 
WITH CHILDHOOD-ONSET TYPE 1 
DIABETES IN FINLAND
Lena Sjöberg
ACADEMIC DISSERTATION
To be presented, with the permission of the Faculty of Medicine 
of the University of Helsinki, for public examination in lecture room 13, 
University main building, on 27 April 2018, at 12 noon.
 
Helsinki 2018
Supervisors  Professor Risto Kaaja
   University of Turku
   Turku, Finland
   Professor Jaakko Tuomilehto
   National Institute of Health and Welfare
   Helsinki, Finland
   Docent Janne Pitkäniemi
   Finnish Cancer Register
   Helsinki, Finland
   and the Department of Public Health
   University of Helsinki
   Helsinki, Finland
Reviewers  Docent Ulla Ekblad
   University of Turku
   Turku, Finland
   Docent Saara Metso
   University of Tampere
   Tampere, Finland
Opponent  Docent Hans Thulesius
   University of Lund
   Lund, Sweden
Cover photographs by Cecilia Toivanen (Spring and Summer) 
and Lena Sjöberg (Autumn); all photographs edited by Robert Toivanen
ISBN 978-951-51-4153-8 (pbk.)
ISBN 978-951-51-4154-5 (PDF)
Unigrafia
Helsinki 2018
3CONTENTS
Terms and Abbreviations ..............................................................................................5
List of original publications ...........................................................................................6
Abstract .........................................................................................................................7
Tiivistelmä .....................................................................................................................9
Sammanfattning ..........................................................................................................11
1 INTRODUCTION .................................................................................................... 13
2 REVIEW OF THE LITERATURE ............................................................................. 15
2.1 Features of type 1 diabetes and reproductive health  ...................................... 15
2.2 Fertility in women with childhood-onset type 1 diabetes ............................... 15
2.3 Termination of pregnancy and type 1 diabetes ................................................ 18
2.4 Type 1 diabetes and female sterilisation  ..........................................................20
2.5 Pregnancy and type 1 diabetes ..........................................................................20
2.6 Menopausal age in women with type 1 diabetes ..............................................20
2.7 The relationship between parity and mortality:  
 does type 1 diabetes modify it? ..........................................................................24
2.8 Previous studies involving the cohort ...............................................................24
3 AIMS OF THE STUDY ............................................................................................25
4 MATERIAL AND METHODS  .................................................................................26
4.1 Presentation of the study cohort .......................................................................26
4.2 Register data  ......................................................................................................27
4.3 Questionnaire survey .........................................................................................27
4.3.1 Assessment of menopause ...............................................................29
4.3.2 Non-response and non-consent  ......................................................29
4.4 Ethical considerations........................................................................................29
4.5 Design and statistical methods .........................................................................29
5 RESULTS ................................................................................................................34
5.1 Fertility and family size ......................................................................................34
5.2 Terminations of pregnancy and sterilisation ...................................................35
5.3 Menopausal age and factors associated with it ................................................38
5.4 Parity and mortality  ..........................................................................................40
46 DISCUSSION .........................................................................................................42
6.1	 Main	findings ......................................................................................................42
6.2	 Interpretation	of	the	findings ............................................................................43
6.2.1 Fertility ...............................................................................................43
6.2.2 Terminations of pregnancy and sterilisation ..................................44
6.2.3 Menopausal age and factors associated with it ...............................45
6.2.4 Parity and mortality ..........................................................................46
6.3 Methodological considerations .........................................................................47
6.3.1 Data sources  .....................................................................................47
6.3.2 Questionnaire study ..........................................................................47
6.4 Strengths and limitations of the study  .............................................................48
7 CONCLUSIONS AND IMPLICATIONS FOR FURTHER STUDIES ......................... 50
Acknowledgements .......................................................................................................... 51
References ...................................................................................................................54
Original publications ........................................................................................................63
5TERMS AND ABBREVIATIONS
df = Degrees of freedom
Fecundity – The capacity to have children
Fertility – Several meanings: one of them is the capacity to have children, but in 
this study the word is used to describe the observed number of children of a person 
Hazard (intensity) = a quantity expressing conditional probability of an event in 
a short time interval, given the event has not happened before
Hazard ratio (HR) = ratio of the hazard rate in the index group and the reference 
(control) group
Hysterectomy – Surgical removal of the uterus (womb)
Macrosomia – Large birth weight 
Oophorectomy – Surgical removal of both ovaries 
Parity – The number of pregnancies of a woman resulting in childbirth 
SD= standard deviation
SIR = ratio of the incidence rate in the index group and reference group, adjusting 
for	age	in	the	reference	group.	Can	be	stratified	by	sex.
T1D = type 1 diabetes
WHO = World Health Organization
6LIST OF ORIGINAL PUBLICATIONS
This thesis is based on the following publications:
I Sjöberg L, Pitkäniemi J, Haapala L, Kaaja R, Tuomilehto J.  
Fertility in people with childhood-onset type 1 diabetes.  
Diabetologia	2013;	56(1):	78−81.
II Sjöberg L, Kaaja R, Gissler M, Tuomilehto J, Tiitinen A, Pitkäniemi J. 
Termination of pregnancy and sterilisation in women with childhood-
onset type 1 diabetes. 
	 Diabetologia	2017;	60	(12):	2377−2383.	
III Sjöberg L, Pitkäniemi J, Harjutsalo V, Haapala L, Tiitinen A, 
 Tuomilehto J, Kaaja R.
 Menopause in women with type 1 diabetes.  
Menopause	2011;	18(2):	158−163.	
IV Sjöberg L, He L, Kaaja R, Tuomilehto J, Pitkäniemi J.  
Parity and mortality in cases of childhood-onset diabetes mellitus.  
Diabetes Metabolism Research and Reviews 2016; 32(6): 607–614.
The publications are referred to in the text by their roman numerals.
7ABSTRACT
The aim of this study was to explore the development of reproductive health issues 
in women with childhood-onset type 1 diabetes (T1D) in Finland in recent decades, 
based on a large population-based cohort. 
The study cohort consists of 2327 women and two individually matched control 
persons without diabetes for each person in the cohort. The cohort is part of the 
DERI (Diabetes Epidemiology Research International) cohort that was established 
at the beginning of the 1980s and it consists of all Finnish persons who were 
diagnosed with T1D at the age of seventeen or under in 1965–1979. The control 
persons are age-, sex- and birth place-matched persons without diabetes. Three of 
the studies are register-based cohort studies that compare women with and without 
diabetes in regard to four topics: family size, rates of terminations of pregnancy and 
sterilisation, and parity-related mortality. Studies I and IV also include men, both 
from the DERI cohort (n = 2819) and from the control group. The fourth study 
was	a	questionnaire	study	on	menopausal	age	and	factors	affecting	it,	involving	
part of the study cohort. The survey results regarding age at menopause of persons 
with T1D were compared with general population data.
The study women had fewer children than the controls without diabetes: the 
average number of children was lower in women with diabetes (1.1 [95% CI 1.03, 
1.15]) than in women without diabetes (1.83 [95% CI 1.77, 1.87]), but in younger 
birth	cohorts	a	significant	trend	was	seen	towards	decreased	differences	between	
women	with	and	without	diabetes.	There	were	significantly	more	terminations	
of pregnancy among women with diabetes (standardised incidence ratio [SIR] 
1.67	[95%	CI	1.51−1.86]	compared	with	control	women)	and	the	indications	for	
termination	were	different:	maternal	medical	 indications	comprised	23.6%	of	
terminations in the diabetes group and 0.3% in the women without diabetes. 
Sterilisations	were	more	common	(SIR	1.69	[95%	CI	1.56−1.83]	in	the	diabetes	
group and 22.9% them were carried out for maternal medical indications, the 
corresponding	figure	among	the	control	women	being	0.3%.	The	difference	between	
women with and without type 1 diabetes regarding the frequency of sterilisation 
vanished around the year 2000.
Age at menopause was associated with the grade of complications of diabetes: 
the age-related occurrence of menopause was higher in women with severe 
microvascular complications, i.e., proliferative retinopathy or end-stage renal 
disease. The mean age at menopause was not lower than in the general population. 
Mortality was lower in persons with children than in childless persons in our 
study, independent of sex and diabetes status, but the relationship between parity 
and	mortality	was	different	in	men	and	women:	in	women	with	diabetes,	having	
8even one child was associated with lower mortality from diabetes compared with 
childless	women,	whereas	in	men,	the	difference	was	seen	only	in	men	with	two	
children or more. 
The	studies	 indicate	that	differences	 in	reproductive	 issues	between	women	
with and without childhood-onset T1D have decreased over time. Compared with 
women without diabetes, parity has been lower and the frequencies of terminations 
of pregnancy and sterilisations have been higher in women with T1D than in the 
general	 population.	 There	 are	 differences	 in	 parity-related	mortality	 between	
women and men with T1D; the underlying reasons and mechanisms are not clear. If 
pregnancy	has	a	protective	effect	in	women	with	T1D,	this	could	partly	be	explained	
by the fact that women with diabetes learn to maintain good metabolic control 
during pregnancy and that they are also motivated to keep up this good control 
after giving birth.
A high quality of life is a central aim of good diabetes care. Future studies should 
focus	on	factors	affecting	the	fecundity	and	fertility	of	women	with	diabetes	and	
whether an improvement in fertility also improves prognosis and quality of life.
9TIIVISTELMÄ
Tämän tutkimuksen tavoitteena oli selvittää tyypin 1 diabetesta lapsuudesta saakka 
sairastaneiden naisten lisääntymisterveyteen liittyviä tekijöitä viime vuosikym-
menten aikana laajan väestöpohjaisen kohortin avulla.
Tutkimuskohorttiin kuuluu 2327 naista ja heidän yksilöllisesti poimitut verrok-
kihenkilönsä, jotka eivät sairasta diabetesta, kaksi verrokkia kohortin jokaista naista 
kohti. Kohortti on osa kansainvälistä DERI-kohorttia ((Diabetes Epidemiology 
Research International), joka luotiin 1980-luvun alussa. Kohorttiin sisällytettiin 
kaikki Suomessa vuosina 1965–1979 syntyneet henkilöt, joilla todettiin tyypin 1 
diabetes ennen 18 vuoden ikää. Verrokit ovat iän, sukupuolen ja syntymäseudun 
suhteen kaltaistettuja henkilöitä, joilla ei ollut diabetesta. Kolme neljästä osatut-
kimuksesta on rekisteripohjaisia kohorttitutkimuksia, joissa diabetesta sairastavia 
naisia ja verrokkinaisia verrataan toisiinsa neljän eri tekijän suhteen: perhekoko, 
aborttien ja steriloinnin ilmaantuvuus sekä lapsilukuun suhteutettu kuolleisuus. 
Osatutkimuksiin I ja IV sisältyvät myös DERI-kohortin miehet (n=2819) ja heidän 
verrokkinsa. Neljäs osatyö oli vaihdevuosi-ikää ja siihen vaikuttavia seikkoja sel-
vittävä kyselytutkimus, johon kutsuttiin osa DERI-kohortista. Kyselytutkimuksen 
tuloksia verrattiin väestötietoihin.
Diabetesta sairastavat naiset saivat vähemmän lapsia kuin verrokit, jotka eivät 
sairasta diabetesta: lasten keskimääräinen lukumäärä oli alempi diabetesryhmässä 
(1.1 [95 % CI 1.03, 1.15]) kuin verrokkiryhmässä (1,83 [95 % CI 1,77, 1,87]), mutta 
nuorimmissa syntymäkohorteissa näkyi merkitsevä muutossuunta ryhmien välis-
ten erojen vähenemiseen. Diabetesta sairastavilla naisilla oli merkitsevästi enem-
män raskaudenkeskeytyksiä (standardoitu ilmaantuvuussuhde SIR 1,67 [95 % CI 
1,51, 1,86] verrattuna verrokkinaisiin).  Raskaudenkeskeytysten syyt olivat myös 
erilaiset: äidin terveyteen liittyvät syyt olivat taustalla 23,6 prosentissa kaikista 
diabetesta sairastavien naisten keskeytyksistä, kun taas verrokkiryhmässä vastaa-
va osuus oli 0,3 %. Sterilointeja tehtiin enemmän diabetesta sairastaville naisille 
(SIR 1,69 [95 % CI 1,56, 1,83] ja niistä 22,9 % tehtiin terveyteen liittyvistä syistä; 
vastaava osuus verrokkiryhmässä oli 0,3 %. Ryhmien välinen ero sterilointien 
ilmaantuvuudessa katosi vuonna 2000. 
Vaihdevuosi-ikä liittyi diabeteskomplikaatioiden asteeseen: ikään liittyvä vaih-
devuosi-ilmaantuvuus oli korkeampi naisilla, joilla oli vaikeita mikrovaskulaarisia 
komplikaatioita, eli silmien verkkokalvojen uudissuonimuodostusta (proliferatii-
vista retinopatiaa) tai vakavia munuaismuutoksia. Keskimääräinen vaihdevuosi-ikä 
ei ollut alempi kuin väestössä yleensä.
Lapsettomien henkilöiden ikään suhteutettu kuolleisuus oli suurempi kuin 
lapsia saaneiden, riippumatta sukupuolesta tai diabeteksesta, mutta lapsiluvun ja 
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kuolleisuuden välinen suhde oli erilainen naisilla ja miehillä. Diabetesta sairastavilla 
naisilla jo yhden lapsen saaneiden naisten kuolleisuus oli alempi kuin lapsettomien 
naisten, kun taas miehillä ero ilmaantui vasta kahden lapsen kohdalla.
Tutkimus osoittaa, että diabetesta sairastavien ja sairastamattomien naisten 
väliset erot ovat vähentyneet ajan myötä. Diabetesta sairastamattomiin naisiin 
verrattuna diabetesta sairastavilla naisilla on ollut vähemmän lapsia, enemmän 
raskaudenkeskeytyksiä ja enemmän sterilisaatioita. Lapsiluvun suhde kuolleisuu-
teen on erilainen diabetesta sairastavilla naisilla kuin miehillä; tämän eron syitä 
ei tiedetä. Mikäli raskaudella on diabetesta sairastavaa naista suojaava vaikutus, 
se voi osittain liittyä siihen, että naiset oppivat raskausaikana saavuttamaan dia-
beteksen hyvän hoitotasapainon ja ovat motivoituneita ylläpitämään sitä myös 
synnytyksen jälkeen.
Hyvä elämänlaatu on diabeteksen hyvän hoidon keskeinen tavoite. Tulevat 
tutkimukset voisivat keskittyä hedelmällisyyteen ja lapsilukuun vaikuttaviin teki-
jöihin sekä selvittämään, parantaako lapsiluvun kasvu myös naisten ennustetta 
ja elämänlaatua. 
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SAMMANFATTNING
Syftet med denna studie var att beskriva hur reproduktionsrelaterade hälsofrågor 
hos kvinnor med typ 1-diabetes utvecklats i Finland under de senaste årtiondena, 
baserat på en omfattande populationsbaserad kohort. 
Studiekohorten består av 2327 kvinnor och två individuellt utvalda kontroll-
personer utan diabetes för var och en av kohortpersonerna. Kohorten ingår i den 
internationella DERI-kohorten (Diabetes Epidemiology Research International), 
som	grundades	i	början	av	1980-talet.	Kohorten	omfattar	alla	finländare	som	fick	
diagnosen typ 1-diabetes före 18 års ålder under åren 1965–1979. Kontrollperso-
nerna	är	personer	utan	diabetes,	som	är	individuellt	matchade	beträffande	ålder,	
kön och födelseregion. Tre av delstudierna är registerbaserade kohortstudier som 
jämför kvinnor med och utan diabetes med avseende på fyra faktorer: barnantal, 
frekvensen av aborter och steriliseringar samt mortalitet i relation till barnantalet. 
Studierna I och IV inkluderar också män, både i DERI-kohorten (n=2819) och i 
kontrollgruppen. Den fjärde studien var en enkätstudie kring menopausåldern 
(övergångsåldern) och faktorer som påverkar den; denna studie omfattade en del 
av kohorten. I enkätstudien jämfördes resultaten med data från tidigare popula-
tionsbaserade studier. 
Kvinnor	med	typ	1-diabetes	fick	färre	barn	än	kvinnorna	 i	kontrollgruppen:	
medelantalet barn var lägre hos kvinnorna med diabetes (1,1 [95 % CI 1,03, 1,15]) 
än hos kontrollpersonerna utan diabetes (1,83 [95 % CI 1,77, 1,87]), men i de yng-
re	åldersgrupperna	observerades	en	signifikant	trend	i	riktning	mot	en	minskad	
skillnad	mellan	grupperna.	Bland	kvinnorna	med	diabetes	förekom	signifikant	fler	
avbrytanden av graviditeter (standardiserad incidenskvot [SIR] 1,67 [95 % CI 1,51, 
1,86] jämfört med kvinnor i kontrollgruppen) och de bakomliggande grunderna för 
avbrytandena var olika: hälsoskäl hos modern utgjorde 23,6 % av avbrytandena i 
gruppen	med	diabetes	och	0,3	%	i	kontrollgruppen.	Steriliseringar	var	signifikant	
vanligare i gruppen med diabetes (SIR 1,69 [95 % CI 1,56, 1,83]) och 22,9 % av 
dem utfördes av hälsoskäl, medan motsvarande andel bland kontrollgruppens 
kvinnor	var	0,3	%.	Skillnaderna	mellan	grupperna	beträffande	steriliseringsfrek-
vens utjämnades kring år 2000.
Menopausåldern var associerad med graden av diabeteskomplikationer: me-
nopausförekomsten i relation till åldern var högre hos dem som hade svåra mik-
rovaskulära komplikationer, dvs. proliferativ retinopati (ögonbottenförändringar 
med nybildning av blodkärl) och svår nefropati (diabetisk njursjukdom). Meno-
pausåldern var i medeltal inte lägre än i den övriga befolkningen.
Mortaliteten i relation till ålder var lägre bland personer som hade barn jäm-
fört med barnlösa personer, oberoende av kön och diabetesstatus. Förhållandet 
12
mellan barnantal och mortalitet var olika bland kvinnor än bland män: bland 
kvinnor med diabetes var mortaliteten lägre bland kvinnor med minst ett barn 
än bland kvinnor utan barn, medan motsvarande skillnad bland män sågs enbart 
hos män med minst två barn.
Studien visar att skillnaderna i reproduktiv hälsa mellan kvinnor med och utan 
typ 1-diabetes har minskat med tiden. Kvinnor med typ 1-diabetes har fått fär-
re	barn	samt	genomgått	fler	aborter	och	steriliseringar	än	kvinnor	i	den	övriga	
befolkningen. Förhållandet mellan barnantal och mortalitet vid typ 1-diabetes är 
olika bland kvinnor och män; de underliggande orsakerna är okända. Ifall gra-
viditet	har	en	skyddande	effekt	med	tanke	på	livet	efter	graviditeten,	kunde	det	
delvis förklaras med att kvinnor med typ 1-diabetes lär sig upprätthålla en god 
diabeteskontroll under graviditeten och att de är motiverade att upprätthålla denna 
kontroll också efter förlossningen. 
God livskvalitet är ett centralt mål för god diabetesvård. Framtida studier bör 
fokusera på faktorer som påverkar fruktsamheten och fertiliteten hos kvinnor med 
diabetes samt på huruvida en ökad fertilitet också förbättrar kvinnors prognos 
och livskvalitet.
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1 INTRODUCTION
Type 1 diabetes (T1D), also called insulin-dependent diabetes mellitus, is a disease 
where the patients are dependent on externally administered insulin because of 
absolute	or	relative	insufficiency	of	insulin.	The	incidence	of	T1D	varies	in	different	
countries; Finland is the country with the highest incidence in the world (1); in 2015, 
62.3/100	000/year	(2).	T1D	has	a	large	impact	on	the	everyday	lives	of	affected	
individuals	and	 its	effects	are	also	reflected	by	 lower	 life	expectancy	compared	
with that in the general population (3–5). 
The impact of T1D on female reproductive health has not been greatly studied. 
According to the WHO, reproductive health “addresses the reproductive processes, 
functions and system at all stages of life” (6). Pubertal development, family 
planning, pregnancy, giving birth, infertility and menopause are all reproductive-
health issues. 
Recent trends in reproductive health in the general population in Finland are 
well documented and population-based registry data is regarded as very reliable 
(7–10). The incidence of terminations of pregnancy has decreased over the years 
and is lower than in the other Nordic countries (8.2/1000 women of fertile age 
in	2015)	(11).	The	total	fertility	rate,	defined	as	the	number	of	children	a	woman	
would have during her lifetime if she survived until the end of her fertile years and 
gave	birth	to	the	average	number	of	children	specific	for	her	country	of	residence,	
was	1.71	 in	2014	 in	Finland,	which	was	the	second	lowest	figure	 in	the	Nordic	
countries. The total fertility rate is higher in the Nordic countries than in Europe 
in general. The rates of stillbirth, neonatal mortality and perinatal mortality in 
Finland are among the lowest in the world (12). Maternal mortality has been almost 
nonexistent since the start of the 1980s and the absolute number of maternal 
deaths varies between 1 and 7 per year (13). Sterilisation rates in Finland increased 
from the 1980s onwards and then decreased after 2000; the relative proportion 
of sterilisation procedures performed on women has decreased (14).
Among other things, questionnaire studies are needed to explore age at 
menarche, to distinguish between voluntary and involuntary infertility, and to 
establish menopausal age. In Finland, it has been estimated that the median 
menopausal age is 51 years (15). 
Before 1922, when the use of insulin started in the treatment of persons with 
T1D, survival for more than two years after diagnosis was very rare and there 
are only very few records of observations on reproductive health from that era 
(16). Within a decade after the introduction of insulin treatment, it was noted 
that	women	with	T1D	differ	 from	women	 in	 the	general	population	 in	several	
ways regarding reproductive health. Many of these features are still considered 
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characteristic of women with T1D: later onset of pubertal development (16–18), 
irregular menstruation patterns (18,19), fewer children (19,20), more stillbirths 
(21),	more	adverse	pregnancy	outcomes	(21,22),	more	birth	defects	in	the	offspring	
(23) and earlier menopause (24) than in the general population. 
Much	effort	has	gone	towards	preventing	complications	of	diabetes,	including	
those related to pregnancies of women with pre-pregnancy diabetes, i.e. pregnancy 
complications, stillbirths and birth defects. In 1989, representatives from all 
European countries and the World Health Organization agreed unanimously 
upon	the	Saint	Vincent	Declaration,	which	has	several	five-year	 targets	within	
the framework of reduction of the burden of diabetes. One of these targets was 
to “achieve pregnancy outcome in the diabetic woman that approximates that 
of the non-diabetic woman” (25). During the years that have passed since 1989, 
much	progress	has	been	made,	but	 there	are	still	significantly	more	pregnancy	
complications, stillbirths, and cases of perinatal mortality and birth defects related 
to pregnancy in women with T1D than in pregnancies in general (22), Finland 
included (26). Among pregnancy complications, those most commonly studied 
are pre-eclampsia, preterm delivery and macrosomia. According to the results 
of a Swedish study carried out in 2009, the risk of pre-eclampsia is more than 
fourfold, that of very preterm birth is threefold and that of foetal macrosomia more 
than tenfold in women with T1D compared with those in the general population 
(21). General population trends in Finland are also seen in women with T1D: 
obesity	 in	pregnant	women	with	T1D	is	 increasing,	which	potentially	can	affect	
the	complication	profile	(21,27).
Microvascular complications of diabetes, such as retinopathy and nephropathy, 
greatly impair the quality of life of persons with diabetes. Nephropathy is one of the 
main	factors	influencing	morbidity	and	mortality	in	people	with	T1D	(4).	It	has	been	
estimated that diabetic nephropathy is present in 2.5−5% of pregnancies of women 
with T1D (28). Diabetic microangiopathy often progresses during pregnancy. (29) 
It is, however, unclear if the changes that appear during pregnancy are reversible or 
not. According to previous studies, the progression of microangiopathy is reversible 
in most cases, as regards both retinopathy and nephropathy, but the more severe 
the pre-pregnancy situation, the higher the risk of permanent progression (30,31). 
Since	the	pre-conceptional	degree	of	both	complications	is	considered	to	affect	the	
risk of further progression of the angiopathies (32), pre-pregnancy counselling 
is particularly important when retinopathy or nephropathy is present before 
pregnancy. 
This study was started in order to investigate whether the general improvements 
in	reproductive	health	issues	are	reflected	in	the	reproductive	health	of	women	with	
type 1 diabetes, and which factors are particularly associated with reproductive 
health in women with type 1 diabetes in the 21st century.
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2 REVIEW OF THE LITERATURE
2.1 Features of type 1 diabetes and reproductive health 
The	most	important	factor	influencing	the	effect	of	T1D	on	female	reproductive	
health, including development of the foetus, is hyperglycaemia. The frequency of 
hyperglycaemic episodes during pre-pregnancy life after the diagnosis of diabetes 
and during pregnancy is important; the more hyperglycaemic periods during 
pregnancy, the higher the risks of congenital anomalies and spontaneous abortion 
(33,34). The occurrence of diabetic complications, i.e. nephropathy, retinopathy, 
neuropathy	and	macroangiopathies,	also	influences	family-planning	decisions	and	
family size. 
Poor	metabolic	control	during	the	first	 trimester	of	pregnancy	significantly	
increases the risks of stillbirth and birth defects (23,35), and it also increases the 
risk	of	spontaneous	abortion	(34).	Hyperglycaemia	affects	several	biochemical	
pathways during foetal development (33,36) and is regarded as the main factor 
causing the above-mentioned pregnancy-related problems in women with T1D.
In	the	last	trimester	of	pregnancy,	metabolic	control	also	affects	professionals´	
decisions on mode and timing of delivery, at least indirectly, as hyperglycaemia 
in the second and third trimester of pregnancy is considered one of the main 
aetiological factors behind foetal macrosomia (27,28), and macrosomia is one of 
the main indications for Caesarean section in women with T1D (37,38). 
2.2 Fertility in women with childhood-onset type 1 diabetes
The word “fertility” is used in several ways in the literature. Most commonly, 
fertility	 is	defined	as	 the	capacity	 to	reproduce.	In	our	study,	 the	term	fertility	
is used in its demographic meaning and it is estimated by the average observed 
number	of	offspring	of	a	person.	To	describe	the	capacity	to	produce	offspring,	
the	more	specific	word	“fecundity”	is	used,	a	word	that	cannot	be	misinterpreted.	
Women with T1D tend to have fewer children on average than women in the 
general population  (20,39,40). There are, though, very few studies that have clearly 
shown that the fecundity of women with T1D is lower than that of other women 
(41,42), although there are potential mechanisms by which that could be the fact. 
The fertile period of life has generally been considered to be shorter in women with 
T1D because of delayed menarche (18) and premature menopause (24). 
Table 1 shows previous studies on this topic. Three of them, one from Japan, 
one from France and one from Germany, were hospital-based. Two of them were 
16
focused	on	marital	status	and	number	of	offspring	in	persons	with	T1D	(40,43).	The	
Japanese	investigators	compared	the	number	of	offspring	with	general-population	
data obtained through an earlier survey (40), whereas the French study concerned 
only comparison between women and men with T1D (43). The third study was a 
German	cross-sectional	study	from	2012	(39),	where	the	main	finding	was	that	
persons with T1D had fewer children than the background population. Jonasson 
et al. (20) carried out a large register study in Sweden. They found that women 
with T1D had fewer children than the general population and, furthermore, they 
detected	a	decreasing	difference	compared	with	the	general	population.	In	more	
recent birth cohorts, the number of children approached that of other women. This 
particularly concerned women who had uncomplicated diabetes.
There are two previous studies that have been carried out in an attempt to 
explore the extent to which women with T1D want to restrict their family size 
because of diabetes. Neither of these studies is recent (19,44). In an American 
study from 1985, there were 37 women who had been diagnosed with T1D before 
the age of 20; eleven of them (30%) had decided not to have children because of 
their diabetes (44). In a Danish study from 1992, more than half of the respondents 
(111/197)	with	diabetes	reported	that	having	the	condition	influenced	their	attitude	
towards having children. The proportions of women with involuntary infertility 
did	not	differ	between	women	with	and	without	diabetes.	(19)
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Table 1. Studies related to the num
ber of off
spring in w
om
en w
ith T1D
.
Reference
Aim
Study design
N
Results 
Aono et al. 2000 
Japan  
(40)
To investi
gate the lifestyle 
and social circum
stances of 
persons w
ith T1D
. M
arriage 
status and num
ber of 
children w
ere included. 
H
ospital-based questi
onnaire 
study. Com
parison w
ith 
general-populati
on data 
obtained via an earlier 
nati
onw
ide survey. 
659 w
om
en 
w
ith T1D
54.7%
 of the w
om
en w
ith T1D
 had no 
children, 37.5%
 had one child, 7.8%
 
had tw
o and none had m
ore than tw
o 
children. 
Sobngw
i et al. 2003 
France 
(43)
To com
pare m
arital status, 
num
ber of off
spring and 
incidence of T1D
 in the 
off
spring, betw
een m
en and 
w
om
en w
ith T1D
 
Hospital-based: data from
 
pati
ent records and pati
ent 
interview
s
78 w
om
en 
w
ith T1D
 
35%
 of the w
om
en had no off
spring 
(corresponding figure for m
en: 8%
),  
43%
 of w
om
en (and 61%
 of m
en) had 
tw
o or m
ore off
spring. N
o com
parison 
w
ith persons w
ithout diabetes.
Jonasson et al. 2007 
Sw
eden 
(20)
To assess ferti
lity in w
om
en 
w
ith T1D
 and the risk of 
congenital anom
alies in their 
off
spring
N
ati
onw
ide register study 
covering 1965−2004
5978 w
om
en 
w
ith T1D
The standardised ferti
lity rate 
(observed num
ber of births / expected 
num
ber of births) varied betw
een 
0.63 and 0.82 and w
as higher in m
ore 
recent birth cohorts.
H
olstein et al. 2012 
Germ
any 
(39)
To assess the num
ber and 
sex rati
o of off
spring of 
persons w
ith T1D
Regional cross-secti
onal 
study, com
parison w
ith 
background populati
on 
364 w
om
en 
w
ith T1D
A
ges 18−49: ferti
lity rate 0.88 in 
w
om
en w
ith T1D
, 1.36 in w
om
en 
w
ithout T1D
. A
ges 41−45: 36.2%
 of 
w
om
en w
ith T1D
 w
ere childless (and 
20%
 of w
om
en w
ithout T1D
).
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2.3 Termination of pregnancy and type 1 diabetes
Women	with	T1D	have	been	advised	to	use	efficient	contraceptive	methods	ever	
since it became evident that there are many risks involved for a woman with 
T1D	and	her	offspring,	especially	 if	conception	occurs	when	the	blood	glucose	
control	of	 the	mother	 is	not	optimal.	The	strongest	efforts	 to	prevent	adverse	
effects	 in	 the	offspring	have	been	 focused	on	preventing	women	with	diabetes	
from having any children at all (45). To date, experts have agreed that women with 
diabetes and coronary heart disease should not get pregnant, which is considered 
important mainly for the prognosis of the mother; neither should those with severe 
nephropathy or retinopathy (46).
In earlier days, if a woman with T1D and suboptimal glucose control became 
pregnant she was often advised to undergo termination. This was practiced in 
Finland	 in	 the	 1970s,	 although	 there	was	no	official	national	 or	 international	
consensus on the circumstances under which and at what gestational stage a 
pregnancy should be terminated (47). There are some previous studies (Table 2) 
on the incidence of termination of pregnancy among women with T1D in Europe. 
They all show that termination of pregnancy is more frequent among women with 
T1D (48–52) and that a larger proportion of these terminations have maternal 
medical indications than those performed among all women (51,52). Many of the 
previous studies lack information on indications for termination of pregnancy.
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Table 2. Studies on term
ination of pregnancy in w
om
en w
ith type 1 diabetes.
Reference
Aim
Study design
N
Results 
Term
inati
on indicati
ons
N
ielsen et al. 1993 
D
enm
ark 
(52) 
To describe the 
outcom
e of all 
pregnancies am
ong 
T1D
 w
om
en 
Retrospecti
ve, hospital-
based study in a 
geographically defined area 
during a 15-year period
205 w
om
en,  
328 pregnancies
Pregnancy term
inati
ons:  
12.5%
 of all pregnancies
M
aternal m
edical reasons:  
24%
 of all term
inati
ons 
(other indicati
ons not 
stated)
Casson et al. 1997 
England 
(49)
To m
onitor 
pregnancies am
ong 
T1D
 w
om
en for 
pregnancy loss, foetal 
grow
th and congenital 
m
alform
ati
on
H
ospital-based populati
on 
cohort study in a 
geographically defined area 
over five years
355 w
om
en,  
462 pregnancies
Pregnancy term
inati
ons: 
5.2%
 of all pregnancies
No data on m
aternal 
m
edical indicati
ons. Foetal 
m
edical indicati
ons: 37.5%
Lorenzen et al. 1999 
D
enm
ark 
(50) 
To describe the patt
ern 
of m
iscarriage and 
sti
llbirths in w
om
en 
w
ith T1D
Populati
on-based 
questi
onnaire study in a 
geographically defined 
area; general response 
rate: 84%
, response rate 
to term
inati
on-related 
questi
ons: 78%
1218  w
om
en, 
1285 off
spring
Pregnancy term
inati
ons:  
17.9%
 of all pregnancies
N
o data on indicati
ons
Penney et al. 2003 
Scotland 
(51) 
To determ
ine 
pregnancy outcom
e in 
w
om
en w
ith T1D
Prospecti
ve, hospital-based 
study over a one-year 
period
273 w
om
en and 
pregnancies
Pregnancy term
inati
ons: 
7.3%
 of all pregnancies
30%
 of term
inati
ons: foetal 
m
edical indicati
ons,  
70%
: socioeconom
ic 
indicati
ons 
M
cG
rogan et al. 2014 
United Kingdom
 
(48) 
To investi
gate 
pregnancy losses in 
T1D
 and T2D
 w
om
en 
Retrospecti
ve study 
uti
lizing prim
ary-care 
records during a 14-year 
period in a geographically 
defined area
548 w
om
en w
ith 
T1D
,  
667 pregnancies
Pregnancy term
inati
ons: 
9.1%
 of all pregnancies
67%
 for non-m
edical 
reasons; no data on 
m
aternal versus foetal 
m
edical indicati
ons 
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2.4 Type 1 diabetes and female sterilisation 
Sterilisation was considered the most reliable contraception method before 
hormonal intrauterine contraceptive devices were introduced. There are 
previous studies that have shown that sterilisation procedures are more 
common among women with T1D than among women without diabetes: 
23% vs. 10% according to a Danish study (53), and 5.8% vs. 3.7% of women in a 
British study (54) used sterilisation as contraceptive method. In 1978, a group of 
American	opinion	leaders	in	the	social	and	medical	field	published	a	text	directed	
to young people with diabetes, and their doctors, stating that women with diabetes 
who	were	older	than	thirty-five,	women	who	had	had	diabetes	for	more	than	twenty	
years and women with serious diabetic vascular complications should strongly 
consider sterilisation (55).
After the arrival of hormonal intrauterine devices (IUDs), the rate of sterilisation 
declined in Finland (14). The present study does not include any data on the use 
of such IUDs among women with T1D – neither are there any previous data on 
sterilisations performed among Finnish women with T1D.
2.5 Pregnancy and type 1 diabetes
Although	much	effort	has	been	directed	to	reducing	factors	related	to	the	elevated	
risks associated with childbearing in women with T1D, there are still pregnancy 
complications that are far more common in this group of women: preterm delivery, 
intrauterine growth retardation, pre-eclampsia, stillbirth, perinatal death, congenital 
anomalies	and	high	birth	weight	of	the	offspring	(22).	Poor	metabolic	control	and	
diabetic nephropathy in early pregnancy increase the risk of all adverse outcomes 
of pregnancy (22,28). The accumulation of factors related to the pregnancy-related 
risks	influence	individual	decisions	on	family	size	(19).	
2.6 Menopausal age in women with type 1 diabetes
Menopause	marks	the	end	of	the	fertile	period	of	a	woman´s	life.	Menopause	is	
defined	as	the	cessation	of	menstruation,	but	menopausal	age	cannot	be	defined	
before one year has passed without menstrual bleeding, i.e. retrospectively (56). The 
timing of menopause matters: early menopause has in some studies been associated 
with a higher risk of coronary heart disease and a higher mortality rate (57). 
Women with T1D are at a higher risk of cardiovascular disease than other 
women (58). Early menopause is considered a cardiovascular risk per se (57) – or, 
on	the	other	hand,	some	claim	that	an	unfavourable	cardiovascular	risk	profile,	as	
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seen in T1D, brings menopause forward (59). These factors contribute to the fact 
that menopausal age matters, especially for women with T1D. 
Studies on menopausal age in women with T1D are listed in Table 3. The 
first	study	on	menopausal	age	in	women	with	diabetes	who	had	received	insulin	
therapy was published in Sweden in 1954: Bergqvist collected information on 37 
women who were 45 years or older at the time of the study and with diabetes onset 
between 18 and 44 years of age. There were 19 women in this study who reported 
that their menstruation had stopped, at the average age of 47.9 years. There were 
ten women over 45 years of age who were still premenopausal (60). At that time, 
the	differentiation	of	diabetes	mellitus	 into	 type	1	and	type	2	was	not	yet	well	
established – although the fundamental study on this had been published as early 
as 1936 (61) – and both the study by Bergqvist and its referenced studies included 
persons	some	of	whom,	on	the	basis	of	descriptions,	would	nowadays	be	defined	
as having type 2 diabetes. The conclusions of that report were that menopause 
occurs slightly earlier in women with diabetes than in the general population, but 
the author remarked that conclusions should be made with caution.  
The next study on menopausal age in women with T1D was published in 2001 
by	Dorman	et	al.	(24).	In	their	study,	there	was	a	statistically	significant	difference	
in menopausal age between women with T1D and the control women without 
diabetes, of whom half were sisters of the women with diabetes. 
The	participants	in	Dorman´s	study	were	diagnosed	with	insulin-dependent	
diabetes at the age of 17 or under in 1950–1964 and recruitment to the study 
was hospital-based. Of the women who were contacted, 71% responded. Their 
parents and siblings were asked to participate as control persons, as were 
population controls from the same geographical regions as the study persons. 
The participants were 143 study persons with diabetes, 186 sisters without diabetes 
and	160	population	controls.	The	women	with	diabetes	differed	significantly	from	
those without diabetes in the following baseline characteristics: the women with 
diabetes had more autoimmune thyroiditis, they were older at menarche, had more 
menstrual irregularities at under 30 years of age, had not used oral contraceptives to 
the same extent, had fewer children, and had lower BMI and lower yearly income. 
When	exploring	age	at	menopause,	T1D	was	the	most	significant	risk	factor	of	early	
menopause; others were being nulliparous, having had menstrual irregularities 
at under 30 years of age and having had unilateral oophorectomy. Menopausal 
age among women with T1D was 41.6 years; 8.3 years earlier compared with their 
sisters and 6.4 years earlier compared with other controls. 
In another American study (62), women with diabetes reported a mean 
menopausal age of 44 years, compared with 50 years in those without diabetes. 
There were 29 participants with diabetes who had reached menopause. The 
objective of this study was to explore the association between coronary artery 
calcium and menstrual dysfunction on the one hand, and birth control use on the 
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other	hand,	and	the	difference	in	the	mean	menopausal	ages	was	an	incidental	
finding.	The	classification	of	diabetes	into	type	1	and	type	2	was	not	necessarily	
correct in all cases, a fact pointed out by the authors. 
The other two studies published on this subject support the interpretation 
that	menopausal	age	in	women	with	T1D	does	not	differ	from	that	in	the	general	
population (63,64). In a Dutch study published in 2015, women with diabetes 
were recruited through several hospitals and the national diabetes society. The 
control persons without diabetes were part of an existing study cohort. There was 
no	significant	difference	 in	menopausal	age	between	women	with	and	without	
diabetes (64). No data on diabetes complications was available. The other study 
on this topic, carried out after our study, is from the United States, by Kim et al. 
Its	main	purpose	was	 to	compare	two	different	kinds	of	diabetes	 treatment	 in	
relation	to	the	incidence	of	menopause.	Age	at	menopause	did	not	significantly	
differ	between	the	groups;	it	was	49.9	and	49.0	years,	respectively,	in	the	intensive	
treatment group versus the conventional treatment group (63). In this study, 
there was no association between menopausal status and autoimmune disease 
or severe microvascular complications; in fact, there were very few participants 
with severe retinopathy or nephropathy. There is a recent study carried out in 
the same centre as the study mentioned above, the main purpose of which was to 
explore a possible association between markers of ovarian ageing, vascular health 
and	diabetes.	The	investigators	found	no	significant	difference	in	Anti-Müllerian	
hormone levels, which are considered a marker of ovarian ageing, between women 
with and without T1D. The participants were relatively young, which might have 
influenced	the	results	(65).
There are two main hypotheses regarding the possible mechanisms of early 
menopause in women with T1D: that it results from autoimmune mechanisms or 
that it has a vascular aetiology. An autoimmune aetiology is supported by the fact 
that anti-ovarian antibodies are often seen both in premature ovarian failure and 
in autoimmune diseases, including T1D (66,67). 
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Table 3. Studies related to m
enopausal age in w
om
en w
ith type 1 diabetes.
Reference
A
im
 of the study
Study design
Num
ber of study 
persons
Results regarding 
reproducti
ve factors
Bergqvist 1954 
Sw
eden 
(60)
To evaluate the gonadal functi
on of 
w
om
en w
ith diabetes
Clinical study
37
M
enopause occurs “slightly 
earlier” in w
om
en w
ith 
diabetes
D
orm
an et al. 2001 
USA 
(24)
To study m
enopausal age and 
factors associated w
ith it in w
om
en 
w
ith type 1 diabetes com
pared 
w
ith their sisters and populati
on 
controls w
ithout diabetes
Hospital-based study on 
w
om
en w
ith T1D
; siblings 
and geographically m
atched 
persons as controls
143 + 186 + 160
M
enopause occurs earlier 
in w
om
en w
ith T1D
 – the 
reproducti
ve life span in 
w
om
en w
ith T1D
 is 6 years 
shorter
Snell-Bergeon  
et al. 2008 
USA 
(62)
To determ
ine w
hich factors 
influence the developm
ent of 
coronary artery disease in persons 
w
ith type 1 diabetes
Clinical case-control study
293 w
om
en w
ith 
T1D
, 319 w
om
en 
w
ithout
M
enopausal age: T1D
 44 
± 13 (SD
) years, control 
w
om
en 50 ± 4 years
Kim
 et al. 2014 
USA 
(63)
To determ
ine the im
pact of 
intensive versus conventi
onal T1D
 
treatm
ent on m
enopause
Random
ized controlled trial
652 (follow
-up: 
564)
M
enopausal age: 49.9 
years (intensive treatm
ent), 
49.0 years (conventi
onal 
treatm
ent)
Yarde et al. 2015 
N
etherlands 
(64)
To determ
ine w
hether m
enopause 
occurs earlier in w
om
en w
ith T1D
Cross-secti
onal study 
(questi
onnaire) directed to 
postm
enopausal w
om
en
140 w
om
en 
w
ith T1D
, 5426 
w
om
en w
ithout
M
enopausal age: 49.8 ± 4.7 
(SD
) years in w
om
en w
ith 
T1D
, 49.8 ± 4.1 years in 
w
om
en w
ithout T1D
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2.7 The relationship between parity and mortality:  
 does type 1 diabetes modify it?
In	many	 studies	 carried	 out	 through	 the	 years	 and	 in	 different	 settings,	 an	
association between parity and mortality has been detected, both in men and in 
women (68–70). Mortality is higher in persons without children, and in many 
studies, mortality is lowest in persons with two children. The reasons for this 
are not clear. One of the possible mechanisms might be selection bias due to an 
association between an unhealthy lifestyle and childlessness. Selection bias means 
that persons who have poor general health more often remain childless – because 
of	 their	own	choice	or	even	because	of	difficulties	 in	finding	a	partner.	When	
looking at persons with a longstanding chronic disease, there may be additional 
factors	that	influence	both	finding	a	partner	and	decisions	regarding	childbirth,	
e.g. concern about transmitting the disease to the children and concern about 
progress of the disease (19). 
Type 1 diabetes is associated with a higher mortality rate compared with that 
in the general population (5,71). Children of persons with T1D have a strongly 
elevated	risk	of	acquiring	the	disease	(72,73).	These	facts	might	affect	decisions	
on birth control, but studies exploring this topic are scarce (19).
2.8 Previous studies involving the cohort
The cohort involved in this study was initially created to investigate mortality among 
persons with childhood-onset T1D in four countries: Finland, Israel, Japan and 
the USA (one region in the US). The cohort was named DERI, which stands for 
Diabetes Epidemiology Research International. The cohort is described in more 
detail in Section 4.1.
There have been many publications on mortality in the international DERI 
cohort	in	various	countries	(74–77),	including	comparison	of	mortality	differences	
between countries (78–83). Ten years after the DERI cohort was created, mortality 
differences	between	countries	were	evaluated.	Overall	mortality	was	higher	 in	
Japan than in Finland or Israel (81) and renal disease turned out to be a major 
factor behind the excess mortality in Japan (78). Suicide was most frequent in 
Finland (81). Violent deaths among male persons with T1D were more frequent in 
Finland and the USA than in Japan or Israel (79). In Finland, there was a greater 
sex	difference	in	mortality	than	in	the	other	countries,	males	having	a	significantly	
higher mortality rate than women (79). 
25
3 AIMS OF THE STUDY 
This mainly register-based study is focused on the reproductive health of Finnish 
women with childhood-onset type 1 diabetes mellitus compared with population-
based	control	women	without	diabetes.	The	specific	aims	addressed	in	the	four	
studies were to explore:
1. Fertility and family size of women with type 1 diabetes 
2. The prevalence rates of termination of pregnancy and sterilisation in 
women with type 1 diabetes
3. Age at menopause in women with type 1 diabetes
4. Mortality in women with type 1 diabetes in relation to family size.
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4 MATERIAL AND METHODS 
This study is based on data on Finnish women diagnosed with childhood-onset 
type 1 diabetes in 1965–1979. Three of the included studies are retrospective and 
register-based; one is a cross-sectional survey. In two of the four articles included 
in this study, Studies I and IV, men are also included. They belong to the same 
cohort as the women. This thesis is focused on women; some comparisons are made 
with men in the cohort, when relevant from the viewpoint of reproductive health.
4.1 Presentation of the study cohort
The international Diabetes Epidemiology Research International (DERI) cohort 
was established to study mortality among those with childhood-onset T1D in 
population-based cohorts in Finland, Israel, Japan and the United States. The 
Finnish DERI cohort was established at the beginning of the 1980s. The persons in 
the DERI study were diagnosed with T1D at 18 years of age or under in 1965–1979 
and placed on insulin at diagnosis. In the nationwide register, 5,166 Finnish cases 
were	identified.	Identification	of	the	persons	in	the	cohort	has	been	considered	
to	be	virtually	complete.	Details	regarding	the	 identification	are	described	 in	a	
thesis published in 1993 (84). The thesis itself concerns a cohort comprising more 
individuals than the established DERI cohort used in this study; the Finnish DERI 
cohort	was	defined	in	line	with	the	international	DERI	cohorts,	as	described	above,	
the essential characteristics being age at onset and date of diagnosis of T1D. 
In Finland, a control group for the DERI cohort was established in the 1980s 
from the national database on reimbursement of drug costs for diabetes, located at 
the Social Insurance Institution. From the National Population Register, two control 
persons	for	each	person	with	diabetes	 in	the	cohort	were	 identified.	They	were	
matched for birth year, geographical birth region and gender. All control persons 
who had been discharged from hospital with a diagnosis of diabetes mellitus (data 
from	the	Hospital	Discharge	Register	[HDR])	or	who	had	offspring	with	a	spouse	
with diabetes (data from the Population Register Centre) were excluded. Persons 
with	Down´s	syndrome	(data	from	the	HDR)	were	also	excluded	from	both	the	
group of persons with diabetes and from the control group. The control group was 
established during collaboration between the National Institute of Health (renamed 
in 2009 as the National Institute of Health and Welfare) and The Social Insurance 
Institution of Finland. Data on the control group was utilized in Studies I, II and 
IV. The control group has so far not been utilized in any other studies than this.
27
For this study, people who died before the age of 14 were also excluded, since 
the study deals with reproduction, which is highly unlikely before the age of 14. 
After all exclusions, the data contains information on 2307 women with diabetes 
and 4530 women without diabetes. 
4.2 Register data 
In Studies I, II and IV, data from the following sources were used:
1. The Social Insurance Institution of Finland 
2. The Hospital Discharge Register of the National  
Institute for Health and Welfare
3. The Population Register Centre
4. The Medical Birth Register (BR) of the National  
Institute for Health and Welfare
5. The Register on Induced Abortions
6. The Register on Sterilisations
7. Statistics Finland 
When the cohort was established and when the control persons were 
selected, the Social Insurance Institution of Finland provided data on medication 
reimbursement: persons who had applied for reimbursement of costs arising from 
insulin treatment of T1D and who were under 18 years of age on the day of diagnosis 
were included in the cohort.
The Hospital Discharge Register (HDR) was utilized when exploring the number 
of live births (Studies I and IV), the number of terminations of pregnancy and 
sterilisations (Study II), and causes of death (Study IV). The Population Register 
provided	us	with	data	 that	 links	parents	and	offspring	(Studies	I	and	IV).	The	
Medical Birth Register (BR) formed the basis of Study II, as did the Registers on 
Induced Abortions and Sterilisations. For Study IV, information on causes of death 
was provided by Statistics Finland.
4.3 Questionnaire survey
The data presented in Study III were obtained by way of postal questionnaires 
that were sent to women in the DERI cohort who were born before 1963. The 
year 1963 was selected because women born after that were considered unlikely 
to	have	reached	menopause	in	2002,	when	the	study	started.	The	first	set	of	the	
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first	round	of	questionnaires	 (n	=	50)	was	sent	 in	October	2002.	The	first	set	
was also used as a pilot study, after which the questionnaire was evaluated and 
minor	changes	were	made.	The	first	round	was	completed	by	the	end	of	2003.	
Looking	at	the	replies	in	the	first	round,	it	was	evident	that	so	few	persons	had	
reached menopause that the second round had to be postponed until three years 
had passed, in order to obtain more end points in the study. 
In Study III, comparison was made with general population data based on 
previous population surveys.
Born before 1963 and 
alive in 2002: 
1 057 women
The DERI cohort: 
2 327 women
Alive at the age of 14: 
2 307 women
Could be contacted: 
978 women
Responded: 
644 women (65.8 %)
Eligible: 
640 women
635 ques�onnaires
sent
Responded: 
526 women (82.8 %)
Dead before age 14: 
20 women
Born a�er 1963 or dead
before 2002: 1 250 women
No valid address, or 
no health service contacts: 
65 women
No response: 
334 women
Three empty forms, one
woman with Turner´s
syndrome
No valid address
three years later: 5 women
First round
Second round
Figure 1. Flow chart of Study III.
The	response	rate	in	the	first	round	was	65.8%.	Three	women	returned	an	empty	
form	and	one	woman	had	Turner´s	syndrome,	leaving	640	eligible	women.	In	the	
second	round,	questionnaires	were	posted	to	those	who	had	replied	in	the	first	
round.	Excluding	those	who	had	died	after	the	first	round	and	those	who	could	
not be reached because of lack of a valid address, 635 questionnaires were posted. 
The response rate in the second round was 82.8%; 526 completed questionnaires 
were returned. 
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4.3.1  Assessment of menopause
The	menopausal	status	of	 the	respondents	was	defined	mainly	on	the	basis	of	
their reply to the question “Do you still menstruate?” There were also questions 
on the menstrual cycle, contraception, hormonal therapy, surgical procedures and 
menopausal symptoms, to specify the individual situation of each respondent.
4.3.2  Non-response and non-consent 
According to Finnish research ethics rules, study persons cannot be contacted on 
the basis of knowledge that a person has a certain disease according to a register. 
The heads of the hospital districts where the study persons lived were contacted 
and asked for permission to contact potential study persons. Covering letters were 
signed by both the director of the hospital district and our principal investigator. 
Permission to send questionnaires was not obtained for all study persons. Twelve 
persons had not had any recent hospital visits and could therefore not be contacted. 
Another 53 could not be reached because of lack of a valid address. Up to two 
reminders were sent to non-respondents in both rounds. 
4.4 Ethical considerations
All studies followed University of Helsinki guidelines. Studies I, II and IV were 
approved by the ethics committees of the Department of Public Health at the 
University of Helsinki, and the Finnish National Institute of Health and Welfare. 
Study III was approved by the ethics committees of the Finnish National Institute 
of Health and Welfare and the Hospital District of Helsinki and Uusimaa.  
In	every	step	of	the	studies,	effort	has	been	made	not	to	reveal	the	identities	
of the study persons, since the data contains information that can be interpreted 
as being very sensitive. All researchers involved have acted according to the data 
protection principles and the ethics rules of the University of Helsinki and the 
National Institute for Health and Welfare. 
4.5 Design and statistical methods
Table 4 shows designs, aims, primary outcomes and comparisons connected with 
each article or manuscript.
In Study I, fertility (rate) was estimated as the average number of children 
born to a woman during the follow-up period per person. Follow-up started at 
the age of 14 and ended on December 31st, 2007, at the age of 50 or at death, 
whichever	occurred	first.
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Confidence	 intervals	 for	 the	 fertility	 estimates	were	obtained	by	using	 the	
bootstrap	method.	Pearson´s	χ2 test was utilized to compare the attained family 
sizes between women with and without diabetes. 
The	fitted	multistate	intensity	models	consisted	of	six	states	for	persons	with	
T1D	and	persons	without	the	disease:	alive	(no	children),	dead,	first	child,	second	
child, third child and fourth child. Either parental age or calendar date was chosen 
for	the	time	scale	in	this	intensity	model.	Rates	and	95%	exact	Poisson	confidence	
intervals of having children among women with and without diabetes are reported 
together	with	hazard	ratios	(HRs),	95%	confidence	intervals	and	Wald	test	p-values	
between	women	with	and	without	diabetes	as	 regards	first,	 second,	 third	and	
fourth	children,	using	stratified	proportional	hazard	models	by	case-control	pairs.	
The interactions between the categorial birth cohort variable proportional hazards 
model and T1D status were estimated.
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Table 4. M
ethodological aspects of the four studies.
A
rti
cle
Aim
D
esign
Outcom
e
Com
parison
I
Evaluate ferti
lity
Retrospecti
ve 
cohort
Live birth of child
Ferti
lity am
ong T1D
 w
om
en versus ferti
lity am
ong 
non-T1D
 w
om
en (controls)
I
Evaluate att
ained fam
ily size
Retrospecti
ve 
cohort
A
tt
ained num
ber of 
live off
spring
A
tt
ained fam
ily size am
ong T1D
 w
om
en versus 
att
ained fam
ily size am
ong non-T1D
 w
om
en 
(controls)
I
Explore the intensity of having 
children 
Retrospecti
ve 
cohort
Intensity of first, 
second, third etc. child
Intensity rati
o (H
R) = intensity (T1D
) / intensity 
(controls)
II
Explore the associati
on betw
een 
T1D
 and term
inati
ons of 
pregnancy 
Retrospecti
ve 
cohort
Intensity of 
term
inati
on of 
pregnancy
Intensity rati
o (H
R) = intensity (T1D
) / intensity 
(controls)
II
Explore the associati
on betw
een 
T1D
 and sterilisati
on
Retrospecti
ve 
cohort
Intensity of 
sterilisati
on
Intensity rati
o (H
R) = intensity (T1D
) / intensity 
(controls)
III
Evaluate average age at 
m
enopause
Cross-secti
onal 
study (survey)
M
edian age at 
m
enopause
M
edian age at m
enopause in T1D
 w
om
en included 
in the study, m
edian age at m
enopause in Finnish 
w
om
en according to a populati
on survey (15)
III
Evaluate prevalence of diabeti
c 
com
plicati
ons and autoim
m
une 
co-m
orbidity
Cross-secti
onal 
study (survey)
Prevalence of diabeti
c 
com
plicati
ons and 
autoim
m
une co-
m
orbidity
Prevalence rati
o (PR) = rati
o of age-related 
prevalence of m
enopause am
ong w
om
en w
ith and 
w
ithout diabeti
c com
plicati
ons or autoim
m
une 
co-m
orbidity
IV
Evaluate the eff
ect of parity on  
m
ortality
Retrospecti
ve 
cohort
M
ortality by parity
M
ortality rati
o in w
om
en w
ith and w
ithout T1D
 by 
parity (hom
ogeneity of m
ortality rati
os)
IV
Evaluate the eff
ect of parity on 
cause-specific m
ortality
Retrospecti
ve 
cohort
Cause-specific 
m
ortality by parity
Cause-specific m
ortality rati
o in w
om
en w
ith and 
w
ithout T1D
 by parity (hom
ogeneity of m
ortality 
rati
os)
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The main outcomes of Study II were termination of pregnancy, and 
sterilisation. Follow-up started  on January the 1st, 1987, the date when the Birth 
Register was established, and ended either at the time of sterilisation, at the age of 
50, at death or at the end of follow-up  (Dec. 31st,	2011),	whichever	occurred	first.	
The risks of termination of pregnancy and sterilisation were explored by age and 
calendar time period. Because of the known excess mortality among persons with 
T1D, competing risk methods were used for estimating the cumulative incidence 
of sterilisation. When estimating the risk of termination of pregnancy, follow-up 
started at the estimated time of conception and ended at either the time of birth 
of a child or the time of termination. Standardized incidence ratios (SIRs) were 
estimated using reference rates from women without T1D and the obtained 95% 
confidence	interval	(CI)	using	standard	Poisson	regression	in	order	to	adjust	for	
both	age	and	calendar	time	differences	in	intensities	of	termination	of	pregnancy	
and of sterilisation.
Time of menopause was the outcome measure in Study III. To investigate 
factors associated with the outcome among women in the DERI cohort, both cross-
sectional and retrospective epidemiological cohort study designs were applied. 
When it was unclear – based on the survey – whether or not the exposure 
(parity, smoking, autoimmune disease, hypertension, coronary heart disease, 
neuropathy, intermittent claudication, nephropathy or retinopathy, all listed in 
Table 6) occurred before the outcome (menopause), a cross-sectional design was 
utilized, and the association between exposure and outcome was expressed by 
prevalence ratios (PRs). The prevalence ratios were estimated by using a generalized 
linear model. A dichotomous outcome (0 = no menopause, 1 = menopause) was 
assumed to be Poisson-distributed (with log-link function). As the prevalence of 
menopause	was	more	than	10%,	variances	of	PRs	and	95%	confidence	intervals	
were obtained using sandwich estimators. 
For two of the variables, age at diagnosis and age at menarche, a retrospective 
cohort design was applied. The pair of observations in the analysis were the age 
at menopause on the one hand, and an indicator of the age-related occurrence of 
menopause (based on the survey) on the other hand. If menopause had not occurred 
by the time of the questionnaire survey, a person was censored. The association 
between age at diagnosis of diabetes (or age at menarche) on the one hand and 
age at menopause on the other hand was analysed by using standard methods of 
time-to-event analysis: the Kaplan–Meier method was used to obtain estimates of 
cumulative probability of menopause and the proportional hazards (Cox) model 
was used for the assessment of risk factors associated with menopause. 
In Study IV, the	primary	outcomes	were	all-cause	and	cause-specific	mortality.	
Follow-up started at the age of 14 and ended on December the 31st, 2010 or at death, 
whichever	occurred	first.	The	number	of	live-born	children	during	follow-up	and	
the date of birth of each child were also recorded for each study person. The three 
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most common groups of causes of death were diabetes-related deaths, deaths from 
cardiovascular diseases and deaths from accidents, violence and suicides. For these, 
cause-specific	risks	were	estimated.	In	the	control	group	there	were	naturally	no	
diabetes-related deaths and among the persons without diabetes, only deaths from 
cardiovascular disease and accidents/violence/suicides were assessed. 
The	data	was	stratified	on	the	basis	of	case-control	status,	sex,	and	the	number	
of	offspring	(categories:	0,	1,	2,	3	or	more).	Crude	mortality	rates	and	95%	CIs	for	
mortality rates were estimated and the observed numbers of deaths were assumed 
to	be	Poisson-distributed.	We	also	adjusted	for	different	age	distributions	with	
respect to number of children by estimating age-adjusted standardized mortality 
ratios (SMRs) and their 95% CIs for both sexes compared with their matched 
controls without diabetes.    
A multi-state model with time-dependent covariates was used to analyse 
intermediate events (birth of children) (85). Parity can in this context be considered 
an	 internal	 time-dependent	 covariate,	 because	 many	 factors	 affect	 personal	
decisions regarding family size. Parity is related to a phenomenon often referred 
to as reverse causation (86), which means that it is unclear whether low parity 
increases the risk of death or if the increased risk of death causes lower parity. 
Parity can only be estimated for persons who are alive (87) and therefore  the risk 
of mortality was explored by using a multi-state model. 
We	had	to	account	for	parity	in	the	stratified	analysis	when	we	explored	whether	
age at onset of T1D was associated with mortality. Because the persons with later 
onset of T1D in our study cohort were older (belonged to earlier birth cohorts) 
and	thus	had	a	higher	expected	mortality	rate,	we	accounted	for	the	effect	of	age	
by modelling the baseline mortality rate within a two-year interval of age.
Cause-specific	mortality	was	estimated	for	the	three	most	common	groups	of	
causes of death (diabetes-related deaths, deaths from cardiovascular diseases and 
deaths from accidents, violence and suicides) by diabetes status and the number 
of children, utilizing competing risk analysis (87). All analyses were performed by 
using R statistics and the mstate package for multi-state frameworks (88). 
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5 RESULTS
5.1 Fertility and family size
Family	size	attained	during	 follow-up	was	significantly	smaller	among	women	
with T1D (average number of children 1.15) than among control women (1.83) in 
our study. Table 5 shows (cohort-wise) the number of children born to women 
with T1D and controls. Many women in the earlier birth cohorts have reached 
menopause and thus their follow-up is complete regarding family size. Although 
women	in	later	birth	cohorts	are	still	at	reproductive	age,	the	difference	between	
women with and without T1D in the average number of children is roughly the 
same as in earlier cohorts. 
Table 5. Number of women with and without type 1 diabetes and their live-born children during follow-
up, by birth cohort. This is a descriptive table not aimed at testing the difference between women 
with and without diabetes.
Birth cohort Number 
of women 
with T1D
Number 
of women 
without 
T1D
Number of 
children, 
mothers 
with T1D
Average 
number of 
children to 
mothers 
with T1D
Number of 
children, 
mothers 
without 
T1D
Average 
number of 
children to 
mothers 
without 
T1D
1947─1954 240 475 252 1.05 851 1.79
1955─1959 533 1052 598 1.12 2010 1.91
1960─1964 687 1361 856 1.25 2681 1.97
1965─1969 552 1088 648 1.17 1938 1.78
1970─1979 269 533 276 1.03 797 1.50
Sum 2281 4509 2630 1.15 8277 1.83
The	attained	family	size	was	statistically	significantly	smaller	among	women	
with	T1D	than	among	control	women;	Pearson´s	χ2-test in comparison of attained 
family sizes in the two groups: χ2 = 497.7, df = 4, p < 2.2 × 10−16. 
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Figure 2.  Attained family sizes in women with and without diabetes. White shading: no children, light 
grey: one child, mid-grey: two children, dark grey: three children, black: four or more children.
Reproduced with permission from John Wiley and Sons Ltd.
To analyse the association between age at onset of T1D and fertility, we chose 
the	study	persons	who	were	born	in	1957−1965	(half	of	the	women	in	the	cohort),	
because those birth years include women from all categories of ages at onset 
(0−17	years).	 In	these	women,	 later	age	at	onset	of	T1D	was	associated	with	a	
higher probability of having a second child (trend test of hazard ratios: p = 0.002; 
homogeneity test of hazard ratios: p = 0.04). 
The study persons were divided into birth cohorts (birth years 1947−1955, 
1956−1960, 1961−1964, 1965−1969 and 1970−1979) and the hazard ratios of having 
a	first	child	were	explored.	The	difference	between	women	with	and	without	T1D	
was smaller in more recent birth cohorts (homogeneity test of hazard ratios between 
birth cohorts: p = 0.04).
5.2 Terminations of pregnancy and sterilisation
The	main	 finding	 in	Study II was that both terminations of pregnancy and 
sterilisation were more common in women with diabetes than in control women. 
During the 25-year follow-up, there were more terminations of pregnancy 
among women with T1D than among control women: the standardized incidence 
ratio (SIR) in comparison of the termination incidences in the groups was 1.67 (95% 
CI 1.51–1.86). Among the women with T1D, 17.1% of pregnancies were terminated; 
the	corresponding	figure	among	control	women	was	11.5%.	These	figures	represent	
the proportion of pregnancies being terminated among pregnancies ending in 
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either childbirth or termination, since there was no data on spontaneous abortions. 
During our 25-year follow-up, approximately 25% of women with diabetes and 
20% of women without diabetes who experienced a pregnancy had at least one 
termination of pregnancy.
Figure 3. Rates of termination of pregnancy by age (A) and calendar time (B) among T1D women 
and control women. Solid line with circles, women with type 1 diabetes; dashed line with triangles, 
women without diabetes.
Reproduced with permission from John Wiley and Sons Ltd.
When looking at the rate of terminations of pregnancy by age and by calendar 
time, it was observed that among women with T1D the number of terminations 
of pregnancy decreased before the year 2000 and then increased again – a 
phenomenon that was not seen among the women without diabetes. 
Among	the	women	without	diabetes,	the	proportions	of	different	indications	
for	termination	of	pregnancy	did	not	differ	from	the	proportions	in	the	general	
population. The proportions of indications in both groups are shown in 
Figure	4.	The	termination	indications	among	the	women	with	T1D	differed	from	
the indications among the control women: while maternal medical indications 
were almost absent (0.3%) among the control women, they were the reasons for 
23.6% of terminations of pregnancy in the T1D group. 
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Figure 4. Proportions of indications for termination of pregnancy in women with and without T1D. Grey 
bars, women with type 1 diabetes; black bars, women without diabetes.
Reproduced with permission from Springer.
Figure 5: Sterilisation rates by age (A) and calendar time (B) among T1D women and control women. 
Solid line with circles, women with type 1 diabetes; dashed line with triangles, women without diabetes.
Reproduced with permission from Springer.
38
The	other	main	focus	in	Study	II	was	sterilisation.	There	were	significantly	more	
sterilisation procedures among the women with T1D than among control women; 
the standardized incidence ratio was 1.69 (95% CI 1.56, 1.83). As in terminations 
of	pregnancy,	the	indication	spectrum	among	T1D	women	was	very	different	from	
that in the control group: maternal medical indications were the reasons for 22.9% 
of the sterilisations in the T1D group, but only 0.3% of the sterilisation indications 
among control women. 
The	difference	in	sterilisation	rates	between	the	groups	vanished	around	the	
year 2000. At about the same time, the sterilisation rates started to decline in 
both groups. 
Almost all (26 of 27) of the sterilisations performed among childless women 
under the age of 30 concerned women with diabetes. Of all sterilisations performed 
among women under 30 years of age, 141 of 185 (76%) were carried out in women 
with diabetes and 44 of 185 (24%) in women without diabetes.
5.3 Menopausal age and factors associated with it
The respondents in Study III had a median age of 48.3 years. Their median age 
at onset of T1D was 12.9 years. The majority of them (86%) had children and 
56% had more than one child. Neuropathy was reported by 28% and proliferative 
retinopathy by 47%. Nephropathy of some degree was reported by 26%; of these, 
65 reported having progressed to end-stage renal disease. 
Of the 640 eligible respondents with T1D (Figure 1), 87 women had undergone 
hysterectomy and four had chemical menopause as a result of chemotherapy. 
Hormonal contraception (causing amenorrhoea) was used by 30 women (most 
of them had a hormone-releasing intrauterine device). Forty-three women had 
started using hormone therapy for climacteric symptoms before the cessation of 
menses.	The	menopausal	age	of	these	164	women	could	thus	not	be	defined.	These	
cumulative	figures	are	based	on	both	rounds	of	questionnaires.	
Among the 640 respondents in Study III, there were 93 who had experienced 
natural menopause. The median age at menopause was 52.5 years. All factors listed 
in Table 6 were tested for association with age-related occurrence of menopause 
and the only factors that were associated with it were severe microvascular 
complications: women with end-stage renal disease or proliferative retinopathy 
reached menopause earlier than other women.
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Table 6. Characteristics of the women in Study III. 
Q1 and Q3: the 25% percentile and the 75% percentile, respectively, of the distribution of the variable.
Reproduced with permission from Wolters Kluwer Health.
Variable Median Q
1
Q
3
Age at diagnosis of type 1 diabetes (years) 12.9 10.7 15.2
Age at menarche (years) 13 12 15
Age at the time of the study (years) 48.3 45.9 51.0
N %
Parity No children 92 14
One child 189 30
Two or more children 359 56
Smoking status Non-smoker 309 48
Ex-smoker 194 30
Current smoker 133 21
Autoimmune diseases Coeliac disease 38 5.9
Hypothyroidism 171 27
Rheumatoid arthritis 61 9.5
BMI (kg/m2) < 25 361 56
25–30 203 32
> 30 72 11
Hypertension (missing data: 0.5%) 254 40
Coronary disease (missing data: 1.1%) 50 7.8
Neuropathy (missing data: 0.1%) 177 28
Intermittent claudication (missing data: 12%) 53 8.3
Nephropathy (missing data: 0.3%) no nephropathy 473 74
proteinuria 95 15
renal insufficiency 31 5
end-stage renal disease  
(dialysis or renal 
transplantation)
39 6
Retinopathy (missing data: 6%) mild retinopathy 321 53
proliferative retinopathy 285 47
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30 women (most of them had a hormone-releasing intrauterine device). Forty-
three women had started using hormone therapy for climacteric symptoms 
before the cessation of menses. The menopausal age of these 164 women could 
thus not be defined. These cumulative figures are based on both rounds of 
questionnaires.  
Among the 640 respondents in Study III, there were 93 who had 
experienced natural menopause. The median age at menopause was 52.5 
years. All factors listed in Table 6 were tested for association with age-related 
occurrence of menopause and the only factors that were associated with it were 
severe microvascular complications: women with end-stage renal disease or 
proliferative retinopathy reached menopause earlier than other women. 
 
Figure 6. The cumulative probability of menopause as a function of age, 
together with the estimated median age (dotted line).  
Reproduced with permission from Wolters Kluwer Health. 
  
Figure 6. The cumulative probability of menopause as a function of age, together with the estimated 
median age (dotted line). 
Reproduced with permission from Wolters Kluwer Health.
 
Because of access to register data on all women in the cohort it was possible 
to compare the non-respondents with the respondents: those who participated in 
the questionnaire survey were more likely to have had children (p < 0.001) and 
to have had a higher age at diagnosis (p < 0.001). 
5.4 Parity and mortality 
In Study IV, the total mortality rate was much higher in women with T1D (5.3 
per person-millennia) than in women without it (0.9 per person-millennia) 
(p < 2 × 10−16).	All-cause	mortality	in	women	without	children	was	significantly	
higher than in women with children, both among women with diabetes and without 
it	(p	<	0.01).	Having	at	least	one	offspring	was	also	associated	with	a	decreased	
risk of diabetes-related death among women with diabetes (HR = 0.46; 95% CI 
0.31,	0.69).	There	was	a	difference	between	the	sexes:	in	men	with	offspring,	the	
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decrease	in	mortality	rate	compared	with	men	without	offspring	was	less	marked	
among those with diabetes (9% reduction in mortality hazard ratio (HR) with one 
offspring,	47%	with	two)	than	among	those	without	diabetes	(33%	HR	(p	=	0.025)	
and 61% HR (p = 0.023) reduction, respectively). The corresponding decrease 
in	mortality	rate	between	women	with	and	without	offspring	was	 independent	
of diabetes status among women. Furthermore, in men, having only one child 
was not associated with a decreased risk of dying from diabetes, but having two 
children was (Figure 7).
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Figure 7. Diabetes-related mortality ratios (with 95% CI) in men and women 
by the number of live-born children. 
Reproduced with permission from John Wiley and Sons. 
 
Looking separately at different causes of death, there were too few deaths 
from cardiovascular diseases among women without diabetes to allow 
comparison. In deaths from accidents and violence, and suicide, no 
statistically significant difference according to parity was seen in women 
without diabetes, but in women with diabetes, those with two children had a 
significantly reduced risk of dying from these causes.  
Figure 7. Diabetes-related mortality ratios (with 95% CI) in men and women by the number of live-
born children.
Reproduced with permission from John Wiley and Sons.
Looking	separately	at	different	causes	of	death,	there	were	too	few	deaths	from	
cardiovascular diseases among women without diabetes to allow comparison. 
In	deaths	 from	accidents	and	violence,	and	suicide,	no	statistically	 significant	
difference	according	to	parity	was	seen	in	women	without	diabetes,	but	in	women	
with	diabetes,	those	with	two	children	had	a	significantly	reduced	risk	of	dying	
from these causes. 
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6 DISCUSSION 
The aim of this study was to investigate the reproductive health of women 
with childhood-onset type 1 diabetes from a population-based epidemiological 
perspective. 
6.1 Main findings
Women with childhood-onset T1D have fewer children than women without T1D. 
Women in more recent birth cohorts tend to have more children than those in 
older cohorts. The later the age at onset of diabetes, the higher the probability of 
a woman with diabetes to have a second child.
Women with childhood-onset T1D have more terminations of pregnancy in relation 
to the number of birth events, and a greater sterilisation rate than women without 
diabetes. The spectrum of indications for both termination and sterilisation is very 
different	in	women	with	and	without	diabetes,	with	maternal	medical	indications	in	
diabetic	women	being	the	reason	for	more	than	one	fifth	of	cases	of	both	termination	
and sterilisation, whereas such indications are virtually absent in women without 
diabetes.
Menopausal	age	 in	women	with	childhood-onset	T1D	does	not	 seem	 to	differ	
from that in the general population. In individuals with severe retinopathy or 
nephropathy, menopausal age is earlier than in women without microangiopathy.
The mortality rate among women with T1D is higher than in women without 
diabetes. Women with children have a lower mortality rate than childless women, 
regardless	of	diabetes	status,	but	the	difference	in	mortality	rates	according	to	parity	
is not as marked among men. Among women, having one child is associated with 
a	significantly	decreased	risk	of	diabetes-related	death,	and	having	two	children	
is associated with an even lower risk of diabetes-related death.
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6.2 Interpretation of the findings
6.2.1 Fertility
Women with childhood-onset T1D have fewer children than women without 
diabetes	and	the	differences	between	the	groups	diminish	in	later	birth	cohorts.	
No data is available on how many women with diabetes have made a choice on 
their own (or together with their partner) not to have children, how many have 
been	influenced	by	healthcare	professionals	to	make	this	decision	–	or	how	many	
have tried to get pregnant without succeeding. 
Most studies carried out to explore parity in women with diabetes have not 
concerned voluntary versus involuntary infertility (20,39,41,89). A Danish study 
from 1992 was carried out to explore attitudes toward having children among 
women with T1D. More than half of them (111/197) reported that their diabetes 
had	an	influence	on	their	attitude.	
There are only a few studies on involuntary infertility in women with T1D. 
In a recent Norwegian study, pregnant women were asked about their time-to-
pregnancy, i.e. the time taken before becoming pregnant. The participants with T1D 
(n	=	221)	reported	a	longer	time-to-pregnancy	than	other	women;	the	difference	was	
statistically	significant	(41).	An	American	study	concerned	501	couples	who	planned	
pregnancy for twelve months. In couples with a female counterpart with T1D, there 
was	a	non-significant	 trend	towards	 longer	 time-to-pregnancy	than	 in	couples	
without diabetes, and if the woman also had other medical conditions in addition 
to	diabetes,	e.g.	hypothyroidism,	the	difference	reached	statistical	significance	(42).	
Of the respondents in our study (Study III), 27% reported hypothyroidism, which 
potentially	makes	this	a	clinically	significant	factor	as	regards	reduced	fecundity.	
In Study III, the participants were asked whether they had undergone treatment 
for infertility. A total of 611 respondents of 640 (96%) replied to the question and 
26 of them (4%) responded positively. This previously unpublished data indicates 
that	involuntary	infertility	is	not	a	more	significant	problem	in	this	group	of	women	
than in the general population, which is in line with the results of some previous 
studies (19,90). 
There might be many women (couples) who decide not to use contraception, 
but also not to consult a doctor if they fail to become pregnant – which makes 
differentiation	 of	 reasons	 for	 childlessness	 complicated	 (91).	 In	 a	 Scottish	
questionnaire study, four of 56 married women (7%) who had not wanted to have 
children stated that the reason for their childlessness was a chronic disease, but 
they did not report what disease (92). Studies on the extent to which a chronic 
disease	affects	the	probability	of	seeking	medical	help	in	cases	of	fertility	problems	
are scarce. In a general-practitioner-record-based British study the proportion of 
women who were childless by choice was increased in younger cohorts, but the 
authors reported no data on diseases among the participants (93). The researchers 
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were very cautious in asking questions of their study patients and pointed out that 
the matter is very sensitive and that probing into it might produce both distress 
and incorrect replies. Other researchers (39) have also reported having made a 
decision not to ask about individual reasons for childlessness.
Future studies could be aimed at exploring the characteristics of women with 
T1D who do not have any children. Register data on co-morbidity could provide 
some new information. Studying patient data on metabolic control would be 
even	more	valuable	in	differentiating	between	women	with	different	reproductive	
patterns (no pregnancies – only abortions – one or more deliveries). 
6.2.2 Terminations of pregnancy and sterilisation
In 1987–2011, the time interval in the study involving terminations of pregnancy 
and sterilisation (Study II), 0.6% of all sterilisation procedures performed among 
Finnish women had a maternal medical indication (53). This is of the same 
magnitude as in our study, where 0.3% of both terminations of pregnancy and 
sterilization procedures in control women were undertaken for maternal medical 
reasons.	This	indicates	that	our	control	group	reflects	the	general	population	of	
Finland.
In this study, medical reasons were behind 23.6% of terminations of pregnancy 
and 22.9% of sterilisation procedures in women with diabetes. It is probable that 
many of these maternal medical reasons in the cases of termination of pregnancy 
reflect	poor	metabolic	control	in	early	pregnancy,	but	this	could	not	be	verified	
since the only patient records available were the application forms. If this is 
the	 case,	 it	 reflects	 the	 fact	 that	not	all	women	with	T1D	carefully	plan	 their	
pregnancies, or at least they do not succeed in achieving optimal metabolic control 
before conception. Pregnancy planning in women with T1D has increased during 
the last few decades; in a recent Finnish study, 66.2% of pregnancies in women 
with T1D were planned (94). 
In cases of sterilisation, some of the procedures undertaken on the basis of 
maternal medical indications probably are strongly recommended by physicians, 
and some of them are performed according to the wishes of the patient and it is 
difficult	 to	speculate	on	the	proportions	of	 these	two.	Studying	patient	records	
would provide more insight into the individual situations of women with T1D who 
undergo terminations of pregnancy.
Looking	 into	possible	 regional	 differences	 could	 also	provide	new	 insight:	
Do	regional	differences	 in	diabetes	 treatment	 influence	metabolic	control	and,	
subsequently, also the frequency of terminations of pregnancy? A comparison 
between	countries	based	on	 these	differences	 is	another	perspective	 in	 future	
studies.
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The	number	of	terminations	of	pregnancy	in	women	with	T1D	fluctuated:	they	
decreased before the year 2000 and then increased again. This cannot be explained 
by any changes in legislation or guidelines. The phenomenon was not seen in women 
without diabetes. It is probably related to the age distribution in the cohort; during 
the late 1980s and 1990s, a large proportion of women in the cohort were in their 
thirties and had their children at that age. The women with diabetes in our cohort 
seldom had children after the age of 40, whereas the women without diabetes 
had their children more evenly throughout their fertile time period. Women with 
diabetes could have acquired diabetic complications after a relatively long disease 
duration and therefore not wanted to risk their health by having another child, 
which	could	explain	part	of	this	trend.	In	our	cohort,	it	is	difficult	to	estimate	the	
extent to which the general progress in preventing diabetes complications has 
influenced	pregnancy	planning	and	pregnancy	outcomes	in	different	birth	cohorts,	
because there are relatively few women born in the 1970s.
The reasons for the decline in sterilisation procedures in both groups of Finnish 
women after the year 2000 are not clear. One reason may be that sterilisation of 
men has increased steadily (14). The use of hormonal intrauterine devices has also 
increased and they are seen as a safe alternative for birth control. There are no 
statistics	or	recent	Finnish	studies	on	the	use	of	different	contraceptive	methods	
among women with T1D.
6.2.3 Menopausal age and factors associated with it
Our results indicate that T1D does not lead to earlier than average menopause, 
if no severe microvascular complications are present. This is in contrast with the 
results	of	two	previous	studies	from	the	US,	where	menopause	occurred	6−8	years	
earlier in women with T1D than in women without diabetes (24,62). There are 
more recent studies that support our results, both from Europe and from the US 
(63,64), but these studies did not include information about complications. The 
results from the DERI mortality study indicated that persons with childhood-onset 
T1D in the USA had a higher mortality rate and a higher rate of complications 
than	Finnish	persons	with	T1D	(80),	which	might	partly	explain	the	differences	
between the countries regarding menopause issues in women with T1D.   
This is another link in the chain of study results suggesting “normalization” of 
the lives of women with T1D. On the other hand, if proliferative retinopathy and 
end-stage	renal	disease	are	associated	with	earlier	menopause,	there	is	a	definite	
clustering of risk factors in those women with T1D who have microangiopathy.
Interestingly, in our study no association was seen between the age-related 
prevalence of menopause and many of the factors traditionally considered to 
be associated with menopause: BMI, smoking, parity and education level. The 
relatively small sample might explain the fact that none of these associations 
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were seen. None of the autoimmune diseases included in the study (coeliac 
disease, hypothyroidism and rheumatoid arthritis) were associated with the age-
related prevalence of menopause; neither was macroangiopathy (coronary heart 
disease, peripheral arterial disease). The most severe forms of both retinopathy 
and diabetic nephropathy were the only factors associated with the age-related 
prevalence of menopause. This supports the theory that early menopause could 
have a vascular aetiology: the presence of severe microangiopathy often suggests 
poor long-term metabolic control, resulting in arterial changes in various organs, 
including the ovaries – and, on the other hand, an earlier menopause could alter 
the	cardiovascular	risk	profile	in	an	unfavourable	direction.	
Menopause research is impeded by the fact that cessation of menstruation 
does not always mean natural menopause. When studying the menopause and 
especially	menopausal	age,	there	are	several	factors	that	influence	interpretation	
of the results. Lack of menstrual bleeding may be the result of reasons other than 
natural menopause. Hysterectomy/oophorectomy naturally leads to surgical 
menopause. Chemical menopause occurs when menstrual bleeding stops because 
of the use of chemotherapy.
The most common of other reasons for cessation of menstruation is the use 
of hormonal contraceptive methods, mainly hormonal intrauterine devices. If a 
woman starts using hormonal therapy to alleviate climacteric symptoms before 
the natural cessation of menses, age at the time of natural menopause cannot be 
defined.	Among	women	with	severe	renal	disease,	menstrual	bleeding	may	cease	
without the woman having entered menopause (95). All these factors reduced the 
number of women who could in this study be dichotomized as premenopausal or 
menopausal.
6.2.4 Parity and mortality
Type	 1	 diabetes	 still	 affects	 life	 expectancy,	 although	much	 improvement	has	
occurred since the 1920s, when insulin treatment started (96). The association 
between a higher mortality rate and being childless is very complex and needs 
to be assessed by using methodology other than a medical research paradigm; to 
compare this association in women with a chronic childhood-onset disease such as 
T1D and other women also demands a broader perspective than a purely medical 
one. Before drawing the conclusion that low parity leads to a higher mortality rate, 
one must exclude the opposite: that a high risk of mortality results in low parity. 
There	are	sex	differences	in	our	results	regarding	the	association	between	parity	
and mortality in persons with and without diabetes. When looking at diabetes-
related	death,	having	at	least	one	offspring	was	associated	with	a	decreased	risk	
of diabetes-related death among women (HR=0.46; 95% CI 0.31, 0.69); in men, 
no	difference	was	seen	among	those	with	only	one	offspring,	but	in	men	with	two	
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offspring,	there	was	a	significant	decrease	in	diabetes-related	mortality	compared	
with	men	without	offspring.	As	regards	overall	mortality,	the	decrease	in	mortality	
in	persons	with	offspring	compared	with	those	without	offspring	was	much	less	
marked among men with diabetes than in any other group (Figure 7). 
A woman with diabetes commonly undergoes very meticulous control during 
pregnancy in order to ensure normal development of the foetus. Some studies 
have indicated that good motivation, and the information provided to women in 
specialist clinics during pregnancy, support women in maintaining good metabolic 
control	after	delivery	(31,97).	Naturally,	this	does	not	apply	to	men.	This	difference	
might	explain	some	of	the	differences	in	parity-related	mortality	between	the	sexes.	
6.3 Methodological considerations
6.3.1 Data sources 
The cohort that has been studied was established in the 1980s, utilizing the 
registers of The Social Insurance Institution of Finland. Persons who had applied 
for reimbursement of costs arising from insulin treatment of T1D and who were 
under 18 years of age on the day of diagnosis were included in the cohort. Since 
there are virtually none who do not apply for reimbursement of costs, and because 
much	effort	was	made	to	verify	each	case,	the	cohort	has	been	considered	complete.	
The diagnostic criteria applied when the cohort was established are still valid, 
although much more is known nowadays about other forms of diabetes, and more 
diagnostic tests are available. Records of each person potentially suitable to be 
included in the cohort were individually evaluated for the type of diabetes, date 
of diagnosis and age at onset (84). 
When selecting the control persons, they were matched according to sex 
and geographical region. These parameters are relevant, because the incidence 
of	T1D	 is	different	 in	males	and	 females	and	 this	has	also	made	 the	 study	of	
reproductive questions easier. Matching according to geographical region 
diminishes	the	effect	of	any	confounding	factors	related	to	this	aspect.	The	fact	
that the frequency of terminations of pregnancy among our control women was 
equal	to	the	corresponding	figure	in	the	general	population	indicates	that	selection	
of the controls has succeeded. 
6.3.2 Questionnaire study
The	response	rate	in	the	menopause	study	was	66%	in	the	first	round	and	83%	
in the second round. Not all potential participants could be contacted, either 
because of lack of a valid address or because it was not possible to get permission 
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to contact them, since there was no data on any recent health service contacts. Tens 
of women in the cohort had already died when this study started, many of them 
before reaching menopause, resulting in bias if factors related to the causes of death 
are also connected to the age-related occurrence of menopause. Since register data 
was available on all potential participants, it was possible to compare respondents 
with non-participants as regards baseline information. The respondents had more 
children and had been diagnosed with diabetes later in life than the non-participants 
(both	differences	statistically	highly	significant).	How	these	differences	would	have	
affected	the	results	regarding	menopausal	age	is	difficult	to	explore.	If	there	were	
to be a strong association between age at onset of diabetes or parity on the one 
hand and the age-related occurrence of menopause on the other hand, there could 
be	a	significant	bias.	
One potential source of bias in this study is the fact that a major proportion of 
the data is self-reported, including data on retinopathy and nephropathy, where 
information can be misunderstood when passed from doctor to patient. 
6.4 Strengths and limitations of the study 
Because of the large cohort of cases of childhood-onset T1D and good availability 
of external data from other national registers, with virtually complete coverage, it 
was	potentially	possible	to	find	even	small	differences	in	the	parameters	studied.	
The population controls utilized in three of the four studies can be considered to 
be representative, given birth year and location. 
The national reimbursement policy diminishes bias due to regional variation, 
and	national	personal	identification	codes	enable	high-quality	data	linkage.
Since the rate of childhood mortality in Finland is very low (98), causes of death 
are	investigated	in	all	cases	and	all	indefinite	cases	are	carefully	considered.	Hence,	
no diabetes cases are thought to have been missed at the time of establishment 
of	the	cohort.	The	only	exception	could	be	in	1965−1969,	when	causes	of	death	
could not be completely ascertained, although it has been estimated that it is very 
improbable that many cases, if any at all, have been missed (84). 
In Finland, mortality follow-up is virtually complete as a result of reliable register 
data	(99,100)	and	the	fact	that	a	unique	identifier,	a	national	identification	number,	
is used in linkage processes. In only a few cases was there somewhat unclear 
classification	of	the	immediate	cause	of	death.
When fertility was explored, the sources were both The Hospital Discharge 
Register of the National Institute of Health and Welfare (ICD diagnoses of delivery), 
and	linkage	of	mothers	and	offspring	was	through	The	Population	Register.	Since	
almost no children are born outside public hospitals in Finland, the Hospital 
Discharge	Register	might	well	have	sufficed	for	assuring	that	no	births	are	missing.	
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Terminations of pregnancy have been approved by Finnish law since 1950, 
termination for social reasons was legalised in 1971 and illegal terminations of 
pregnancy are considered to have stopped at the start of the 1970s, at the latest. 
Our main data source here was The Register on Induced Abortions. The reliability 
of Finnish registers has been evaluated over the years and they are generally 
considered to be very reliable (7–10,101).
The data source for Study III was a questionnaire. Questionnaires always contain 
self-reported participant data and the participant can choose not to tell certain 
things, or even give false information. 
Regarding menopausal age, which is always self-reported, it has been observed 
that the probability of correct recall has been higher when less time has passed 
since menopause (102). Most of the women who had reached menopause had 
done	so	within	five	years	prior	to	the	survey.	There	was	very	little	inconsistency	
in the reported ages at menopause in women who reported their menopausal age 
in both surveys, sent three years apart. In cases of inconsistency, the reported age 
in	the	first	survey	was	used,	because	it	was	nearer	the	actual	date	of	menopause.	
The main limitations of Study III are related to the general weaknesses of survey 
studies and to the particular weakness of our questionnaire study implementation. 
The participation rate could have been higher had the forms been made more 
anonymous,	e.g.	by	removing	the	participant´s	printed	name	from	the	form	and	
substituting it with a number code. Although the forms were sent in closed envelopes 
(and discreet return envelopes), the name on the form might have mattered to some 
of the potential respondents. The nature of the data gathered via this questionnaire 
was fairly intimate, which probably reduced the number of respondents. 
The present work is connected to childbirth without directly dealing with 
the	offspring	of	the	women	participating	in	the	study.	It	is	very	evident	that	the	
reproductive health of women also involves the well-being of the next generation. 
The	health	of	 the	offspring	affects	decisions	 regarding	 family	planning	and	 is	
therefore in focus in most studies regarding reproductive health matters among 
women with T1D. There are far more previous studies on pregnancy outcome in 
T1D than on the issues covered by our study: family size, terminations of pregnancy, 
sterilisation, menopause and parity-related mortality.
A general problem in research involving parity issues is the varying terminology: 
the term fertility is frequently used imprecisely. In some studies, fertility is explored, 
but when drawing conclusions, the results are interpreted as though they could 
also provide data on fecundity. Exploring quantitative data on family sizes and 
numbers of live births does not include any information on the intentions and 
desires of women who have given birth and those who have not. 
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7 CONCLUSIONS AND IMPLICATIONS  
 FOR FURTHER STUDIES
For women with childhood-onset T1D, the results of our study provide positive 
information. When looking at time trends in fertility, sterilisation and age at 
menopause,	the	differences	between	women	with	and	without	diabetes	as	regards	
many reproductive health issues have decreased with time. This is probably 
partly due to progress in the treatment of diabetes. Good metabolic control and 
improved	treatment	possibilities	combined	with	increased	knowledge	in	the	field	
of reproductive health in T1D encourages women to become pregnant without 
fear of complications due to T1D.  
To go beyond the current register-based studies would deepen our knowledge of 
reproductive health issues in women with T1D. In a prospective setting, metabolic 
control, risk factors, diseases other than diabetes and factors other than health-
related	aspects	 that	 influence	both	reproductive	health	and	mortality	could	be	
identified.	Qualitative	studies	could	provide	data	on	the	reasons	behind	low	parity,	
e.g. in connection with voluntary versus involuntary infertility. Surveys and in-
depth interviews could also give a more nuanced picture of how health professionals 
have	influenced	the	decisions	made	by	women	and	by	couples.	
The sterilisation rate in women with diabetes has reached the rate observed in 
the	general	population.	This	reflects	the	fact	that	no	currently	used	contraceptive	
methods	are	contraindicated	in	women	with	diabetes	–	and	may	also	reflect	the	fact	
that pregnancy seldom is considered totally contraindicated because of diabetes.
If menopausal age is not earlier in women with T1D, the reproductive life span 
is not shorter than in other women. This might decrease worry about whether one 
is in a hurry to have children because of diabetes – if neither macroangiopathy 
nor severe microangiopathy is present.
No	definite	indications	have	been	found	that	there	are	factors	that	influence	
the association between parity and mortality other than the tendency to decide not 
to have (more) children if there are diabetic complications or other factors that 
affect	 the	prognosis,	which	means	that	 the	results	of	 this	study	are	concordant	
with those of previous studies. 
The treatment of T1D has steadily developed in recent decades and studying 
the reproductive health of younger cohorts is important in the future. Those who 
are born in the 21st	century	and	are	diagnosed	with	T1D	receive	all	the	benefits	
from	the	latest	diabetes	research	and	therefore	have	a	different	risk	profile	than	the	
women in our cohort, who were diagnosed in the 1960s and 1970s. The intrinsic 
factors	influencing	the	patients´	motivation	to	maintain	good	metabolic	control	
are,	however,	not	much	different	from	those	in	previous	generations.	
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Appendix 
 
Questionnaire of Study III in Finnish 
Kansanterveyslaitos / HUS Naistenklinikka 
NAISDIABEETIKON TERVEYSTUTKIMUS 
 ⎡ 
 
 
 
 
⎣ 
 
Yleistiedot: 
 
Osoite:  _____________________________________________________________________ 
(mikäli muuttunut) 
 
Puh: __________________________________________ 
 
Sähköposti:  _______________________________________ 
 
 
Diabetestiedot: 
 
Toteamisvuosi:   19 _____ 
 
1.  Onko suvussanne muilla  diabetesta  (nuoruusiän eli tyypin 1 diabetesta)? 
 
 1 kyllä  ---->
 kenellä:____________________________________________________ 
 2 ei 
 3  en tiedä   
 
2.   Missä Teitä hoidetaan diabeteksenne vuoksi? 
 _________________________________________________________________________ 
 
 
3.   Viimeisin HbA1c-arvo (”pitkäaikaissokeri”): _________________ 
 
3.1 Missä  viimeisen vuoden HbA1c-arvot on  mitattu: 
_________________________________ 
 
      Päivämäärät (jos muistatte):________________________ 
2 
 
4.   Onko silmämuutoksia?    
 
 1 Kyllä  ------ > Milloin todettu ensimmäisen kerran?________________________ 
 2 Ei 
 3 En tiedä 
 
4.1 Minkä asteisia muutoksia?  
 
1 Taustaretinopatiaa   
 
 2 Proliferatiivista retinopatiaa 
 3 Ei muutoksia 
 4 En tiedä 
 
4.2. Onko laserhoitoa annettu? 
 1 Kyllä  ------ > kuinka monta kertaa:_________ 
 2 Ei 
 
 
5.  Missä  ja milloin viimeisin silmätutkimus?   __________________________________ 
 
 
6.   Onko munuaismuutoksia?  
 
 1 Kyllä ------ > milloin todettu? ___________________________ 
 2 Ei 
  
6.1 Minkä asteisia muutoksia ? 
 
 1 Valkuaista virtsassa 
 2 Munuaisten vajaatoimintaa 
 
6.2. Onko munuaisten vajaatoiminta vaatinut dialyysin tai munuaistensiirron? 
 
 1 Kyllä  
 2 Ei 
 
7.  Onko teillä todettu kohonnut verenpaine ( > 140/90 mmHg)?  
 
 1 Kyllä 
 2 Ei 
 
 
3 
 
7.1 Käytättekö  verenpainelääkettä?  
 1 Kyllä  ------ > minkä 
nimistä?______________________________________________ 
 2 En 
  
 
8.  Onko teillä todettu ääreishermoston muutoksia (neuropatiaa)? 
 1 Kyllä 
 2 Ei 
 
 
9.  Onko teillä todettu sepelvaltimotautia?  
 1 Kyllä  ------ > Miten hoidettu:  lääkehoito         pallolaajennus              ohitusleikkaus  
 2 Ei 
 
 
10.  Onko teillä todettu ääreisverenkierron häiriöitä (esim. katkokävelyä)? 
 
 1 Kyllä   
 2 Ei 
 
 
B) Muut sairaudet: 
 
Onko teillä todettu  - ja jos on, miten hoidettu/hoidetaan 
 
 
1.   Kilpirauhassairaus 
 
 1 Kyllä  ------ >  hoito:________________________________ 
 2 Ei 
 
2.   Reumatauti (nivelreuma, Sjögrenin oireyhtymä, LED) 
 
 1 Kyllä   ------ >  hoito:________________________________ 
 2 Ei 
 
3. Astma 
 
 1 Kyllä 
 2 Ei 
4 
 
 
  
4.   Syöpä 
 
 1 Kyllä ------ > minkä elimen syöpä?__________________________________ 
    hoito:______________________________________________ 
 2 Ei 
 
 
5.   Keliakia 
 
 1 Kyllä 
 2  Ei 
   
6.   Muita kroonisia sairauksia 
 
 1  Kyllä  ------ > mitä?___________________________________________ 
    hoito:__________________________________________ 
 2  Ei 
 
7.   Luukato (osteoporoosi) 
 
 
 1  Kyllä 
 2 Ei 
 
  jos on esiintynyt murtumia, niin kirjatkaa tähän minkälaisia 
________________________________________________________________________________
________________________________________________________________________________ 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
D) Gynekologiset esitiedot: 
 
1. Kuukautisten alkamisikä: __________________ 
 
2. Kuukautiskierron pituus: __________________ 
 (kuinka monta päivää kuukautisten alkamisesta seuraavien kuukautisten alkamiseen) 
 
3. Kuinka monta päivää kuukautisvuoto kestää (tai kesti, mikäli ne ovat loppuneet)? 
 ______________pv 
 
4. Onko(oliko) teillä välivuotoja? 
 1 Kyllä 
 2 Ei 
  
    
5. Onko teillä ollut poikkeuksellisen paljon akneongelmia (finnejä)? 
 1 Kyllä 
 2 Ei 
   
6. Kärsittekö mielestänne liiallisesta ihokarvoituksesta?  
 
 1 Kyllä 
 2 En 
 
7. Käytättekö nyt ehkäisypillereitä? 
 1. Kyllä;  merkki:_________________ 
 2. En 
 
 
8. Käytättekö nyt kierukkaa? 
 
 1.  Kyllä      kuparikierukkaa          hormonikierukkaa 
 2.  En  
 
 
 
 
 
 
 
 
 
 
 
6 
 
9. Onko lääkäri määrännyt lisälääkitystä epäsäännöllisten tai poisjääneiden kuukautisten 
takia? 
 
 1. Kyllä   mitä valmistetta ja milloin?________________________________ 
 2.  Ei  
  
10. Kuinka monta raskautta teillä on ollut? 
 
 Synnytyksiä:   ______   
 Keskenmenoja:   ______ 
 Raskaudenkeskeytyksiä (abortteja):______ 
 Kohdunulkoisia raskauksia: ______  
 
11. Onko raskauksien yhteydessä ollut verenpaineen nousua ja/tai valkuaista virtsassa  
 (”raskausmyrkytys”)? 
 1. Kyllä ------ > minä vuonna/vuosina?________ 
 2. Ei 
   
 
12. Ikänne synnytysten yhteydessä: ______________________________________________ 
 
 
13. Oletteko saanut lapsettomuushoitoa? 
 
 1.  Kyllä  ------ > minkälaista ja milloin?_____________________________________ 
 
 2. En 
 
 
14. Onko teillä ollut gynekologisia sairauksia (esimerkiksi tulehduksia, endometrioosi)?  
 1. Kyllä  ------ > minkälaisia sairauksia?___________________________________ 
    Miten teitä on hoidettu?__________________________________ 
2. Ei  
  
15. Onko teille suoritettu kohdunpoistoleikkaus?  
 1. Kyllä  ------ >  minä vuonna?_______ 
 2. Ei 
 
16. Onko teille suoritettu munasarjojen poistoleikkaus? 
 1 Kyllä  ------ > minä vuonna?___________ 
2 Ei 
3 Vain toinen munasarja poistettu 
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E)  Vaihdevuositiedot 
 
 
1. Minkä ikäisenä äitinne koki vaihdevuodet?___________________ 
1. En tiedä 
 
2.Onko äitinne vielä elossa? 
 
1. Kyllä 
 
2. Ei 
 
  
3. Minkä ikäisenä mahdolliset sisarenne kokivat vaihdevuodet?___________________ 
 1. Ei ole sisaria------ siirtykää kysymykseen 6 
 2. Sisarillani ei ole vielä vaihdevuosia 
3. En tiedä 
 
4. Montako elossa olevaa siskoa teillä on? ________siskoa 
      ________sisarpuolta 
  Siskojenne syntymävuodet:________________________________________________ 
  Sisarpuolten syntymävuodet:_______________________________________________ 
 
5. Sairastaako joku siskoistanne diabetesta? 
1. Kyllä, vuonna __________________________syntynyt/syntyneet 
2. Ei 
6. Onko teillä vielä kuukautiset? 
 1. Kyllä 
 2. Ei 
7. Ovatko kuukautisenne harventuneet tai jääneet välillä pois? 
 1. Kyllä 
 2. Ei 
8. Milloin teillä oli viimeiset kuukautiset?__________________ 
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9. Onko teillä viimeksi kuluneen kuukauden aikana ollut seuraavanlaisia oireita (jotka 
saattavat olla merkki vaihdevuosista)? Ilmoittakaa jokaisessa kohdassa oireiden 
voimakkuus (0= ei oireita, 5= sietämättömät): 
 
 1. kuumia aaltoja  
 2. hikoilua 
 3. unettomuutta 
 4. ärtyisyyttä 
 5. sydämentykytystä 
 
10. Käytättekö tällä hetkellä hormonihoitoa? 
 1. Kyllä  -------> valmisteen nimi:  __________________milloin aloitettu: _________ 
 
2. En---------- Oletteko saanut vaihdevuosioireisiin hormonihoitoa aikaisemmin? 
    1.Kyllä; minä vuosina?______________________ 
    2.En koskaan 
 
9. Jos olette saanut hormonihoitoa, onko se auttanut mahdollisiin oireisiinne? 
 
 1. Kyllä 
 2. Ei 
 3. Ei ollut oireita 
4.En ole saanut hormonihoitoa------------ ohittakaa kysymykset 10 ja 11 
 
10. Onko vaihdevuosien hormonihoito aiheuttanut sivuvaikutuksia?  
 1. Kyllä ------ > minkälaisia?________________________________________________ 
 2. Ei 
 
 
11. Vaikuttiko vaihdevuosien hormonikorvaushoito diabetestasapainoonne? 
 1. Kyllä ------- > miten? ____________________________________________
 2. Ei 
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F) Depressio 
 
1. Oletteko joskus hakeutunut lääkärin/psykologin/muun ammatti-ihmisen puheille alakuloisuuden 
tai masentuneisuuden takia?  
  1. Kyllä-------------- milloin?____________________________ 
  2. En 
 
2. Onko teille milloinkaan määrätty lääkitystä masennuksen eli depression hoitoon? 
 1.Kyllä---------  vuosina__________________________________________ 
     Muistatteko mitä lääkettä?___________________________ 
 2. Ei 
 
3. Tunnetteko tällä hetkellä itsenne masentuneeksi? 
1. Kyllä 
2. En 
 
3. Olkaa hyvä ja täyttäkää oheinen lomake (DEPS-masennusseulonta). 
 
G)  Elintavat yms 
 
 
 Paino: ________  Pituus: ____________ 
 
1. Kolesteroliarvonne 
  Milloin viimeksi mitattu: _______________________________ 
1.1 Kokonaiskolesteroli:_____________________  
1.2 HDL-kolesteroli (ns hyvä kolesteroli):______________     triglyseridit: _______________ 
 
 
 
2. Harrastatteko liikuntaa? eli kävelettekö/pyöräilettekö/uitteko/hiihdättekö yli puoli  
 tuntia  kerrallaan ja vähintään 3 kertaa viikossa? 
 
 1. Kyllä 
3. En 
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3. Oletteko koskaan tupakoinut? 
 1. Kyllä 
 2. En------------ siirtykää kysymykseen 4 
 
3.1. Milloin aloititte tupakanpolton? Vuonna __________ 
  
 Tupakoitteko nyt?  
  
 1. Kyllä ------> montako savuketta päivässä? ______ 
 2. En 
 
3.2 Jos olette lopettanut:  milloin lopetitte?________ 
   kuinka monta vuotta tupakoitte kaikkiaan? _______________ 
 
 
4. Käytättekö alkoholia ( 2 annosta tai enemmän, 1 annos= pullo olutta tai lasi viiniä tai 
 4 cl  väkeviä)  
 
 1. päivittäin 
 2. viikoittain  
 3. 1-2 kertaa kuukaudessa 
 4. harvemmin 
5. en lainkaan 
 
5.  Mikä on peruskoulutustasonne? (merkitkää pisin koulutus, vain yksi vaihtoehto) 
1. Kansakoulu, keskikoulu tai peruskoulu 
2. Ammattikoulu/keskiasteen tutkinto (myös nykyinen ammattikorkeakoulu) 
3. Ylioppilastutkinto 
4. Korkeakoulututkinto 
 
 
 
 
______________________________ ________________________________ 
 paikka                  pvm  allekirjoitus 
 
      ________________________________ 
      nimen selvennys 
 
 
KIITOKSIA VAIVANNÄÖSTÄNNE ! 
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Questionnaire, Study III – in Swedish 
 
Folkhälsoinstitutet / HNS, Kvinnokliniken  
 ⎡ 
 
 
 
 
 
⎣ 
HÄLSOUNDERSÖKNING FÖR KVINNLIGA DIABETIKER 
 
Kontaktuppgifter: 
 
Adress:  _____________________________________________________________________ 
(ifall den ändrats) 
 
Telefon: __________________________________________ 
 
E-post:  _______________________________________ 
 
 
Diabetesuppgifter: 
 
 
1.  Har någon av Era släktingar diabetes  (ungdomsdiabetes, dvs  typ 1 diabetes)? 
 
 1 ja   ----> vem/vilka (släktskapsförhållande):_______________________________ 
 2 nej 
 3  vet inte   
 
2.   Var uppföljs Ni pga. Er diabetes (vilken privatläkare, hälsocentral eller  
sjukhuspoliklinik)? 
 _________________________________________________________________________ 
 
 
3.   Senaste HbA1c-värde (”långtidssocker”): _________________ 
 
3.2 Var har det senast gångna årets HbA1c-värden uppmätts: 
_______________________________ 
 
   Hur många gånger per år brukar HbA1c mätas? ________________________ 
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4.   Har ögonbottenförändringar konstaterats?    
 
 1 Ja  ------ > När konstaterades de första gången?________________________ 
 2 Nej 
 3 Vet inte 
 
Vilken grad av ögonbottenförändringar?  
 
1. Bakgrundsretinopati   
 
 2. Proliferativ retinopati 
 3. Inga förändringar 
 4. Vet inte 
 
 
4.2. Har Ni fått laserbehandling? 
 1 Ja  ------ > hur många gånger:_________ 
 2 Nej 
 
 
5. När och var undersöktes ögonbottnarna senast?  
_________________________________________________________ 
 
 
6.   Har njurfunktionen försämrats på grund av diabetes?  
 
 1 Ja------ > När har detta konstaterats? ___________________________ 
 2 Nej 
  
6.1 Vilken grad av förändringar? 
 
 1 Protein (äggvita) i urinen 
 2 Njursvikt 
 
6.2. Har njursvikten lett till dialysbehandling eller njurtransplantation? 
 
 1 Ja 
 2 Nej 
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7.  Har Ni förhöjt blodtryck( > 140/90 mmHg)?  
 
 1 Ja 
 2 Nej 
 
7.1 Använder Ni blodtrycksmediciner?  
 1 Ja  ------ > vilken medicin?______________________________________________ 
 2 Nej 
  
8.  Har Ni konstaterats ha förändringar i nervfunktionerna (neuropati – t.ex. känseln nedsatt 
i fötterna)? 
 1 Ja 
 2 Nej 
 
9.  Har Ni kranskärlssjukdom (hjärtsjukdom med syrebrist i hjärtat)?  
 1 Ja ------ >Vilken behandling:  mediciner             ballongutvidgning by-pass-operation  
 2 Nej 
 
 
10.  Har Ni försämrad blodcirkulation i benen (t.ex. klaudikation = ”fönstertittarsjuka”)? 
 
 1 Ja  
 2 Nej 
 
 
B) Andra sjukdomar: 
 
Har Ni följande sjukdomar?  - ifall ja, hur behandlas/behandlades de 
 
 
1.   Sköldkörtelsjukdomar 
 
 1 Ja ------ >  behandling:________________________________ 
 2 Nej 
 
2.   Reumatiska sjukdomar (ledgångsreumatism, Sjögrens syndrom, LED) 
 
 1 Ja   ------ >  behandling:________________________________ 
 2 Nej 
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3. Astma 
 
 1 Ja 
 2 Nej 
 
  
4.   Cancer 
 
 1 Ja ------ > vilket slag av cancer?__________________________________ 
    Behandling:______________________________________________ 
 2 Nej 
 
 
5.   Celiaki 
 
 1 Ja 
 2  Nej 
   
6.   Andra kroniska sjukdomar 
 
 1  Ja  ------ > vilka?___________________________________________ 
    behandling:__________________________________________ 
 2  Nej 
 
7.   Benskörhet (osteoporos) 
 
 
 1  Ja 
 2 Nej 
 
  Om Ni har haft benbrott, var vänlig och skriv här hurudana 
________________________________________________________________________________
________________________________________________________________________________ 
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D) Gynekologiska uppgifter: 
 
1.  Hur gammal var Ni då Ni fick Er första menstruation? __________________ 
 
2. Menstruationscykelns längd: __________________ 
 (hur många dagar från menstruationens början till följande menstruation) 
 
3. Hur många dagar blöder Ni (eller blödde, ifall Ni inte längre har menstruation)? 
 ______________dagar 
 
4. Har (hade) ni mellanblödningar? 
 1 Ja 
 2 Nej 
  
 
 
7. Använder Ni p-piller för tillfället? 
 1. Ja;  märke:_________________ 
 2. Nej 
 
 
8. Har Ni spiral? 
 
 1.  Ja          kopparspiral     hormonspiral 
 2.  Nej  
 
 
9. Har Ni fått hormonbehandling på grund av oregelbunden eller utebliven menstruation? 
 
 1. Ja                 
 vilket preparat och när?___________________________________ 
 2.  Nej  
  
 
 
10. Hur många graviditeter har Ni haft? 
 
 Förlossningar:  ______   
 Missfall:   ______ 
 Aborter:   ______ 
 Utomkvedshavandeskap: ______  
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11. Har Ni haft förhöjt blodtryck och/eller protein i urinen under graviditet 
(”graviditetsförgiftning”)? 
 
 1. Ja ------ > vilket/vilka år?________ 
 2. Nej 
    
 
12. Hur gammal var Ni då Ni födde Era barn:______________________________________ 
 
 
13. Har ni fått behandling för barnlöshet? 
 
 1.  Ja ------ >         hurudan behandling och när? 
 ________________________________________ 
 
 2. Nej 
 
 
 
14. Har Ni haft gynekologiska sjukdomar (t.ex. infektioner, endometrios)?  
 1. Ja ------ > hurudana sjukdomar?___________________________________ 
    Hurudan behandling har Ni fått för dessa?___________________________ 
3. Nej  
  
 
15. Har Er livmoder opererats bort?  
 1. Ja  ------ >  vilket år?_______ 
 2. Nej 
 
16. Har äggstockarna opererats bort? 
1. Ja ------ > vilket år?___________ 
2. Nej 
3. Endast ena äggstocken bortopererad 
 
17. Har Ni genomgått steriliseringsoperation? 
  
 1 Ja 
  
 2 Nej 
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E)  Uppgifter om övergångsåren 
 
 
1.  Hur gammal var Er mor då hon kom i klimakteriet (dvs. när slutade hennes 
menstruation)?___________________ 
Vet inte ______ 
 
2.  Lever Er mor? 
 
1. Ja 
 
2. Nej 
 
  
3. Vid vilken ålder slutade Era eventuella systrars menstruation?___________________ 
 1. Har inga systrar------ gå till fråga 6 
 2. Mina systrar är ännu inte i klimakteriet 
3. Vet inte 
 
4. Hur många systrar har Ni i livet? ________systrar 
      ________halvsystrar 
 Era systrars födelseår:________________________________________________ 
 Era halvsystrars födelseår:_______________________________________________ 
 
5. Har någon av Era systrar diabetes? 
1. Ja, den/de som är född/födda år __________________________ 
2. Nej 
 
6. Har Ni ännu kvar Er menstruation? 
 1. Ja 
 2. Nej 
 
7. Har Er menstruation ibland uteblivit eller har den börjat komma mer sällan än förut? 
 1. Ja 
 2. Nej 
 
8. När hade Ni Er senaste menstruation?__________________ 
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9. Har ni under den senast gångna månaden upplevt något av följande symptom (som kan 
vara ett tecken på klimakterium = övergångsåren)? Skriv in vid varje symptom hur starka 
symptom Ni haft på en skala från 0 till 5: 
   0=inga symptom, 1=mycket lindriga symptom, 2= lindriga symptom, 3= medelsvåra 
symptom, 4=svåra symptom.  5= olidligt starka symptom: 
 
 1. värmesvallningar (”heta vågor”) 
 2. riklig svettning 
 3. sömnlöshet 
 4. lättretlighet 
 5. hjärtklappning 
 
10. Använder Ni hormonbehandling (annan än p-piller) för tillfället? 
 1. Ja -------> medicinens namn:  _____________________ 
    När har behandlingen påbörjats? _________ 
 
2. Nej---------- Har Ni tidigare fått hormonbehandling för klimakteriebesvär? 
    1.Ja; när?______________________ 
    2. Nej 
9. Om Ni fått hormonbehandling, har den hjälpt mot Era symptom? 
 
 1. Ja 
 2. Nej 
 3. Hade inga symptom 
4. Har inte fått hormonbehandling----------- hoppa över frågorna 10 och 11 
 
10. Har hormonbehandlingen gett biverkningar?  
 1. Ja ------ >  hurudana?________________________________________________ 
 2. Nej 
 
 
11. Har hormonbehandlingen för klimakteriesymptom påverkat er sockerbalans? 
 1. Ja ------- > hur? ____________________________________________________
  
 2. Nej 
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G) Depression 
1. Har Ni någon gång sökt hjälp hos t.ex. läkare eller psykolog på grund av nedstämdhet eller  
              depression?  
 
1. Ja-------------- när?____________________________ 
2. Nej 
 
2.  Har Ni någon gång använt depressionsmediciner? 
 1.Ja---------  under åren__________________________________________ 
    Minns Ni medicinens namn?___________________________ 
 2. Nej 
 
3.  Känner Ni Er deprimerad för tillfället? 
1. Ja 
2. Nej 
 
3.  Var vänlig och fyll i bifogade blankett (DEPS-depressionssållning). 
 
 
 Vikt: ________  Längd: ____________ 
 
1. Era kolesterolvärden 
  När har kolesterolet senast uppmätts? _______________________________ 
 Om Ni känner till de senast uppmätta värdena, var vänlig och skriv in dem nedan. 
1.1 Total kolesterolhalt (S-kol):_____________________  
1.2 HDL-kolesterol (s k godartat kolesterol):______________ triglycerider: ______________ 
 
 
 
2. Motionerar Ni? dvs promenerar/cyklar/simmar/skidar/gymnastiserar Ni minst en 
halv timme åt gången minst 3 gånger i veckan? 
 
 1. Ja 
2. Nej 
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3. Har Ni någonsin rökt? 
1. Ja 
 2. Nej------------ gå till fråga 4 
 
3.1. När började Ni röka? År__________ 
  
 Röker Ni nuförtiden?  
  
 1. Ja ------> hur många cigarretter per dag? ______ 
 2. Nej 
 
3.2 Om Ni slutat: när slutade Ni röka?________ 
   Hur många år rökte Ni allt som allt? _______________ 
 
 
4. Använder Ni alkohol ( 2 portioner eller mer; 1 portion= en flaska öl eller ett glas vin 
eller 4 cl  starksprit)  
 
 1. dagligen 
 2. varje vecka  
 3. 1-2 gånger per månad 
 4. mer sällan 
6. inte alls 
 
5.  Vilken är Er grundutbildning? (endast ett alternativ) 
5. Folkskola, mellanskola eller grundskola 
6. Yrkesskola/mellanstadieutbildning 
7. Studentexamen 
8. Universitets- eller högskoleexamen 
 
 
 
______________________________ ________________________________ 
 ort                 datum                 underskrift 
 
      ________________________________ 
      förtydligande av underskriften 
 
TACK FÖR ATT NI HJÄLPTE OSS! 
 
